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ABSTRACT 
ANALYSIS OF N-LINKED OLIGOSACCHARIDES OF PROSTATE-SPECIFIC 
ANTIGEN AND PROSTATIC ACID PHOSPHATASE IN PROSTATIC FLUIDS 
Krista Yaudes White 
Eastern Virginia Medical School and Old Dominion University, 2009 
Director: Dr. Richard R. Drake 
Presently, prostate cancer is the most common cancer afflicting men in the United 
States, with serum PSA being the "gold standard" protein biomarker used in the clinic for 
detecting and diagnosing prostate cancer. Nonetheless, serum PSA levels can also be 
elevated in non-cancerous conditions as well, such as benign prostatic hyperplasia (BPH). 
Due to this overlap, many unnecessary biopsies and radical prostatectomies occur, 
leading to patient distress. Despite recent advances to clinical assays which consider 
other clinical parameters, there is still a great need for improved clinical detection 
methodologies for prostate cancer, including improved biomarkers. Therefore, this 
research project aims to examine the N-glycosylation patterns of prostate-specific antigen 
(PSA) and prostatic acid phosphatase (PAP) in prostate proximal fluids, as well as to 
examine the total glycan profile for prostate proximal fluids with the intent of discovering 
carbohydrate-based biomarkers for the detection of early prostate carcinomas. To this 
end, preliminary glycomic and proteomic studies were completed using seminal plasma 
samples, based on the disease cohorts normal, BPH, and prostate cancer. These samples 
resulted in sufficient protein levels of both PSA and PAP for glycopeptide and glycomic 
analyses. Furthermore, these studies led to additional knowledge of PSA and PAP 
glycosylation. In addition to this sample set, pools of disease-defined expressed prostatic 
secretions (EPS) were generated and subsequently analyzed for detection of both protein 
levels and carbohydrate structures of PSA and PAP, as well as examined for their total 
glycomic profile. We succeeded in characterizing EPS fluids for both protein and 
carbohydrate content, as well as identified potential carbohydrate targets for the 
generation of new clinical assays for the detection of early prostate carcinomas. These 
targets are fucosylated, complex sub-type glycans which we found to be under-expressed 
in prostate carcinoma samples as compared to their non-cancerous counterparts. We 
believe EPS fluids have utility not only for discovery of cancer biomarkers, but also for 
use in future clinical assays. 
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1.1 Prostate Cancer 
Prostate cancer is the most common and second most fatal cancer afflicting men 
in the United States, excluding non-melanoma skin carcinomas. It is estimated that in 
2009 there were 192,280 new cases of prostate cancer and 27,360 deaths attributable to 
prostate cancer1. Studies show that prostate cancer prevalence is proportional to age2, 
and can lead to ostesclerotic metastases . Additionally, African-American men and men 
with a family history of prostate cancer are at increased risk for developing prostate 
cancer and death due to their cancer1. The human prostate is a small walnut-sized 
glandular male reproductive organ that is located below the urinary bladder and in front 
of the rectum (Figure 1). There are three zones of the prostate (central, peripheral, and 
transition), with each zone being responsible for the three main disorders of the prostate 
in humans, namely prostatitis (infections), benign prostatic hyperplasia (BPH, organ 
enlargement), and carcinoma (malignant tumors)4. The central zone makes up 
approximately 25% of the prostatic glandular tissue, and is responsible for only 1-5% of 
carcinomas. The peripheral zone is the largest zone, is where most cases of prostatitis 
arise from, and up to 70% of carcinomas are located. Finally, the transitional zone is 
responsible for BPH and roughly 20% of carcinomas4 (Figure 1). The American 
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Figure 1. The prostate gland. There are three main zones of the prostate. The central 
zone is responsible for 1-5% of carcinomas, and makes up approximately 25% of the 
prostatic glandular tissue. The peripheral zone is the largest zone, is where most cases of 
prostatitis arise from, and up to 70% of carcinomas are located. Finally, the transitional 
zone is responsible for approximately 20% of carcinomas, and is the location for benign 
prostatic hyperplasia. 
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Urological Association (AUA) recommends for healthy men to start prostate cancer 
screening at age 50 (or as early as 40 for high-risk populations), with screening tests 
inclusive of a serum PSA test and a digital rectal exam (DRE). A PSA value above the 
age-specific median (i.e. 0.7 ng/ml for 40 year old men), or an abnormal DRE (size, 
contour, consistency) may prompt the clinician to recommend a prostatic biopsy. The 
next course of action will be determined based on the biopsy results, which can include 
watchful waiting/active surveillance, radical prostatectomy, radiation therapy, or 
brachytherapy if the presence of localized tumors are detected5. The Gleason score is a 
grading system which aids in determining the severity of a given prostate carcinoma. 
This system is named after Dr. Donald F. Gleason, who developed the technique along 
with other members of the Veterans Administration Cooperative Urological Research 
Group (VACURG)6. The Gleason grading system relies solely on the cellular growth 
patterns of prostate carcinomas, with a higher score indicating increasing cellular 
differentiation. There are nine growth patterns, all of which the Gleason grading system 
organizes into five histological grades6. From these five grades, a score between two and 
ten is assigned to the tumor based on the sum of the primary and secondary grade patterns 
(i.e. grade 3 + grade 4= Gleason score of 7). The primary grade represents the 
predominant pattern present, while the secondary grade represents the second most 
prevalent pattern6. It is imperative to know the two grades comprising the Gleason score, 
as 4+3 is a more severe score of seven than 3+4. The Gleason score, along with a serum 
PSA value and clinical staging of the tumor, allow for a clinician to assess a patient's 
cancer as low, intermediate, or high risk (Table 1). With the abundant advances in 
prostate cancer early detection, it has become evident that many cases involve clinically 
4 
Table 1. Risk stratification schemes for prostate cancer prognosis 




serum PSA value 
<= lOng/ml 
10to20ng/ml 




8 to 10 
Clinical Stage 
Tlcor T2a 
T2b, but not qualifying 
for high risk 
T2c 
Natural History 
Often indolent disease, 
progression uncommon 
Meaningful risk of 
progression that is of 
concern to most patients 
Significant risk of 
progression 
Current clinical practices use a combination of factors to determine the risk of prostate 
cancer progression in men presenting with cancer-positive biopsies. A low risk 
classification indicates that the cancer is not likely to progress to a more severe state; 
with patients typically presenting with serum PSA values less than 10 ng/ml, a Gleason 
score of less than 6, and a clinical staging of Tic or T2a. Classification of intermediate 
risk is based on the patient presenting with a serum PSA value between 10 and 20 ng/ml, 
a Gleason score of 7, or a clinical staging of T2b. These tumors have a moderate 
potential of progressing to more aggressive disease, and treatment options should be 
evaluated. Finally, prostate tumors classified as high risk will most likely progress to 
aggressive disease, with patients presenting with a serum PSA value over 20 ng/ml, a 
tumor Gleason score of 8 to 10, or a clinical staging of T2c. Table adapted from D'amico 
et al., 1998 and Thompson et al., 2007. 
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insignificant prostate carcinomas. This has lead to overdiagnosis of prostate cancer in 
men, and comes along with various other complications that these men may not have 
otherwise suffered from. The U.S. Preventative Services Task Force (USPSTF) 
determined that treatment of prostate cancer due to screening protocols may lead to 
erectile dysfunction, urinary incontinence, bowel dysfunction, and death7. In addition, 
the USPSTF determined that the risks and benefits of prostate cancer screening in men 
under 75 years of age cannot be assessed at this time, and that it is not recommended to 
screen for prostate cancer in men over 75 years old7. 
Prostate Specific Antigen as a Biomarker 
Prostate specific antigen (PSA) is a 28.4 kDa glycoprotein that is secreted by the 
prostatic epithelium. It is synthesized by both healthy and diseased prostate tissue8'9, and 
its transcription is androgen-regulated10. It has a physiological role of liquefying seminal 
fluid11'12, and is thought to do so by proteolytically digesting seminal fluid proteins such 
as semenogelin-1 and -213. This kallikrein serine protease (hK3) was first described in 
1966, further characterized in 1971 by Hara et al14, and first detected using a serum-based 
test in 1980 by Pasidero et al15. PSA levels in seminal fluid are typically within the 
range of 100-400 ug/ml, however they have been reported to be as high as 3 mg/ml16. 
With tight regulation, it is common for only small amounts of PSA to leak into the blood 
stream, leading to serum PSA concentrations to be normally 10-fold lower than PSA 
levels in seminal fluid17. Previously, and as early as 1960, other groups had performed 
various immunological studies and found multiple antigens specific to prostatic tissue18" 
26, some of which were later found to be similar to PSA27"29. Initial studies on "prostate-
specific antigens" were focused on finding markers for chronic prostatitis, infertility, 
forensic purposes, contraception, and cancer . An immunoassay for the detection of 
PSA for prostate cancer diagnoses was developed and refined by Chu et al. in the early 
1980s30"32. Stamey et al. followed up these initial studies with a large study using a 
significantly higher number of serum samples in 1987, finding that PSA serum levels 
correlated with stages of prostate cancer as well as tumor volume, that PSA was a better 
biomarker than the current clinical biomarker prostatic acid phosphatase (PAP), and that 
PSA could also be used as a marker to monitor tumor response to radiation therapy33. 
Clinically, serum PSA levels have been used as a diagnostic marker for prostate cancer, 
with Myrtle et al.34 setting the threshold for serum PSA levels at 4.0 ng/ml in 1986, and 
the U.S. FDA approving PSA as a marker to monitor patients being treated for prostate 
cancer in the same year. PSA was not approved as a diagnostic prostate cancer 
biomarker by the U.S. FDA until 1994. To date, PSA is the clinical biomarker routinely 
measured in serum for detection of early prostate carcinomas33,35'36. However, it has 
more recently been determined that the levels of PSA in serum do not efficiently 
distinguish between non-cancerous prostatic pathologies, such as benign prostatic 
hyperplasia (BPH) and prostatitis, and prostate cancer37"39. Outside of disease, other 
factors such as age, body mass index (BMI), and race also affect serum PSA 
concentrations40. Therefore, the PSA index, which is defined as free PSA (fPSA) 
expressed as a percentage of total PSA (tPSA), has been used to improve PSA 
specificity41. However, this value does not facilitate diagnosing prostate cancer in 
patients with a serum PSA score of less than 10 ng/ml42, and additional studies report that 
there is a 20.5% mean prostate cancer incidence where serum PSA levels were between 
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2.5 and 4.0 ng/ml43. These discrepancies lead to many unnecessary tissue biopsies, 
which in turn decrease patient quality of life, and therefore there is a pressing need to 
improve the specificity of PSA as a biomarker, and continue to evaluate additional 
biomarkers. 
Prostatic Acid Phosphatase as a Biomarker 
Prostatic acid phosphatase (PAP) is a 50 kDa dimeric glycoprotein which is found 
in several human tissues such as platelets, lungs, osteoclasts, erythrocytes, liver and 
kidney44'45, however it is present in 100-fold higher concentrations in human prostatic 
tissue as compared to other organs46. As one of five functions by hydrolyzing organic 
monophosphate esters47. A definitive physiological role of PAP within the reproductive 
tract of men has yet to be established. PAP was the earliest biomarker for prostate 
cancer, and is still used today in the clinic as a marker for metastatic prostate disease48'49. 
PAP was first linked to prostatic tissue in 193534, and subsequently deemed a prostate 
cancer biomarker for the next 50 years34'50. However, with the discovery of PSA and its 
apparent organ specificity, PAP was quickly replaced in part due to the wide-spread 
distribution of acid phosphatase isoenzymes throughout the human body33. The original 
clinical assay for PAP assessed the levels of enzymatic activity in serum, yet early assays 
were unable to determine if the activity detected was from prostate-derived PAP. 
Various techniques were used to try to improve such assays, including the addition of L-
tartrate to inhibit PAP derived directly from human prostatic tissues51, as well as the use 
of thymolphthalein phosphate substrates52. However, these additions still could not 
compete with the serum-based PSA test. Serum PAP's sensitivity was also criticized, 
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and it was found that for early screening, PAP had a sensitivity of 45%, which paled in 
comparison to a value of 96% sensitivity for PSA33. In addition to early screening, serum 
PSA was also found to be a more sensitive marker than serum PAP for prostate cancer 
staging53. In 1997, O'Dowd et al. declared that PAP was no longer useful in the clinical 
staging of early prostate carcinomas54, which truly ended PAP's era as a prostate cancer 
biomarker. 
Additional Prostate Cancer Biomarker Candidates 
In addition to PSA and PAP, other candidate molecules have also been examined 
for their potential at diagnosing and staging prostate cancer. For example, prostate stem 
cell antigen (PSCA) is a glycosylphosphatidylinositol-anchored cell surface antigen 
located primarily in prostatic tissue and is thought to contribute to cellular proliferation 
and signal transduction55. Elevated PSCA levels positively correlate with higher Gleason 
grades in advanced prostate carcinomas, and is also potentially associated with androgen-
independent prostate cancer56'57. However, most of these studies utilize prostate tissue, 
with only one study which detected PSCA in peripheral blood samples58. Additionally, it 
has yet to be determined if PSCA is a better diagnostic marker than PSA34. Prostate-
specific membrane antigen (PSMA) is a type II integral membrane protein which is found 
in the cytosol in normal prostate tissue and in the plasma membrane in prostate cancer 
tissue59'60. PSMA has been studied extensively with results showing that protein serum 
levels increase with prostate cancer and metastatic prostate cancer, and PSMA is 
detectible in both serum and prostate tissue61"65. In addition, another study indicated that 
PSMA levels are much higher in prostate cancer patients as compared to healthy patients 
and patients with BPH . However, more studies are needed to confirm the clinical utility 
of PSMA in early diagnosis of prostate carcinomas34. Transmembrane protease serine 2 
(TMPRSS2) is a transmembrane serine protease which is expressed primarily in prostate 
tissue67. In situ hybridization and microarray studies have shown that TMPRSS2 
expression is androgen regulated, and that TMPRSS2 is expressed in normal and 
cancerous prostate basal cells, unlike other serine proteases, like PSA, which are found in 
the prostate secretory cells67. This indicates the role TMPRSS2 may play in a smaller 
subset of prostate carcinomas, allowing for an additional and alternative route of prostate 
cancer diagnosis. Prostasin is another membrane-bound serine protease, which while it is 
expressed in most human tissues; its expression is highest in prostate tissue68. The 
soluble form of prostasin is easily purified from seminal fluid68, and is N-linked 
glycosylated69, indicating its utility as a prostate cancer biomarker target. These 
candidate biomarkers are all localized to the cell surface and some are found in a secreted 
form as well, demonstrating their potential role in prostate carcinoma, as well as making 
them easier targets than intercellular molecules. Two additional candidate markers for 
prostate cancer, 73-kDa type II Golgi membrane antigen (GP73; GOLPH2) and a-
methyl-Co-racemase (AMACR) are not localized to the cell surface; however they have 
been shown to be tissue-specific, and have proven to still be reliable markers. GP73 is a 
Golgi phosphoprotein which has previously been shown to be a useful serum marker for 
hepatocellular carcinoma70"73. More recently, GP73 mRNA transcripts found in human 
sedimented urine samples have shown effectiveness in diagnosing early prostate 
carcinomas74. Additionally, it has been shown to be upregulated in prostate cancer 
tissues as compared to normal, healthy prostate tissues75, showing its value as a prostate 
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cancer biomarker. Finally, AMACR is primarily localized to the peroxisomes and 
mitochondria within prostatic tissues, and has been found to be overexpressed in prostate 
carcinoma tissues76"78. Its clinically utility has been shown by the relatively high 
sensitivity and specificity AMACR has for diagnosing prostate cancer79. Furthermore, 
genomic and single nucleotide polymorphism (SNP) studies of AMACR have indicated a 
role this gene plays in both early prostate carcinomas and familial prostate cancer80"82. 
Overall, there are many candidate markers for the early diagnosis and prognosis of 
prostate cancer; however, none of these markers, like PSA and PAP, have yet to aid in 
decreasing the number of unnecessary biopsies and radical prostatectomies that still 
afflict many men today. 
1.2 Protein Glycosylation 
Subcellular molecules located both inside and outside the cell and containing 
carbohydrate components are called glycoconjugates, namely glycoproteins, glycolipids, 
proteoglycans, and glycosaminoglycans. Protein glycosylation is a common post-
translational modification which has proven to be a useful disease marker83'84, with many 
studies outlining altered glycosylation patterns in cancerous samples as compared to 
normal healthy samples85'86. Protein glycosylation has long been shown to be altered in 
cancerous tissues as compared to normal tissues, suggesting that characterization of this 
type of post-translational modification could lead to more specific biomarkers in the 
clinic. Proteins become glycosylated in both the endoplasmic reticulum (ER) and the 
Golgi apparatus (Golgi), where post-translational processing occurs prior to transport. 
Fully processed glycoproteins are most commonly found in lysosomes, attached to the 
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outside of the cell surface, and in the extracellular matrix; however there have been 
several examples of both nuclear and cytoplasmic glycosylation87"91, all of which seem to 
be an addition of a single monosaccharide, unlike the complex oligosaccharide structures 
seen on other glycoproteins91. There are two main types of glycosylation of proteins as 
they are processed in the ER and Golgi: O-linked and N-linked (Figure 2). 
O-linked Glycosylation 
O-linked glycosylation occurs in the Golgi apparatus and involves the attachment 
of monosaccharide residues to the hydroxyl group of either serine or threonine in a 
sequential manner. This is achieved by glycosyltransferases present in the Golgi. These 
carbohydrate chains are typically 1-4 units long, and most commonly begin with the 
addition of N-acetylgalactosamine to the protein (Figure 2). Therefore most often O-
glycans refer to the O-GalNAc linkage, although O-GlcNAc and O-mannose are 
alternative linkages. The most common examples of an O-linked glycoprotein are 
mucins, which are a class of secreted and plasma membrane glycoproteins having several 
clusters of O-linked glycans. These proteins contain regions rich in serine, threonine and 
proline residues. 
N-linked glycosylation 
N-linked glycosylation is achieved through a more complex process than O-linked 
modifications and results in three main classes of N-linked oligosaccharides: 1) high-
mannose-type, 2) complex-type, and 3) hybrid-type (Figure 3). A preformed 14-
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Figure 2. Example oligosaccharide structures of O- and N-linked protein 
glycosylation. O-GalNAc is the most commonly observed O-linkage to serine or 
threonine residues on proteins. This representative complex O-GalNAc glycoform can be 
found attached to human respiratory mucins. The most basic O-GalNAc core structure is 
observed linked to a single galactose residue, however it can be extended, branched, and 
terminated by fucose in various linkages, sialic acid in a2-3 linkage, or sialic acid a2-6-
linked to the core GalNAc. N-linked oligosaccharides are typically more complex 
structures as compared to O-linked oligosaccharides, with extensive branching and 
extension off of the universal pentasaccharide core. Adapted from Varki et al, 2009. 
Cartoon representations are as follows: • =GlcNAc, O =Mannose, O =Galactose, A 














Figure 3. N-linked oligosaccharide subtypes. There are 3 distinct subtypes of N-
linked glycans, each based on the type of monosaccharides present in the oligosaccharide 
branching chains. High-mannose structures consist of the core structure plus any number 
of mannose monosaccharides decorating the terminal branches. Complex subtypes 
consist of the core pentasaccharide with any number of monosaccharides and various 
branching patterns. These structures are usually decorated with a combination of N-
acetylglucosamine, N-acetylgalactosamine, galactose, sialic acid and fucose 
monosaccharides. It is also common to see the core N-acetylglucosamine bound by a 
"core" fiicose. Finally, the hybrid subtypes are classified by having one main arm 
resembling a high-mannose structure, while the other arm resembles a complex structure, 
therefore being termed a "hybrid" of these two different subtypes. Cartoon 
representations are as follows: • =GlcNAc, O =Mannose, O =Galactose, A=Fucose, 
•=NeuAc, D=GalNAc 
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to most eukaryotic cells. This compound consists of three glucose, nine mannose, and 
two N-acetylglucosamine molecules and is attached to dolichol by a pyrophosphoryl 
residue. Dolichol is a long-chained polyisoprenoid lipid embedded in the ER membrane. 
The carbohydrate residues are added in a concerted manner by specific enzymes. This 
process begins on the cytosolic face of the ER with the addition of the two GlcNAc and 
five mannose residues in a sequential manner. At this point, the structure "flips" so that it 
is now on the lumenal face of the ER. The next seven carbohydrates (four mannoses and 
three glucoses) are added one at a time from a nucleotide-sugar donor (UDP) to a 
dolichol molecule embedded on the cytosolic face of the ER. The dolichol-sugar moiety 
then flips to the lumen face and each monosaccharide is transferred to the growing sugar 
chain. As a protein is being elongated co-translationally into the ER lumen, an N-linked 
glycosylation site will be recognized and the 14-mer oligosaccharide is transferred to the 
nascent protein chain by an enzyme called oligosaccharyl transferase. The 
oligosaccharide is covalently attached to the amide nitrogen of asparagine residues that 
are followed by any amino acid except proline, followed by either a serine or threonine 
(N-X-S/T). This tripeptide sequence is recognized and triggers the transfer of the 
oligosaccharide from dolichol to the protein en bloc. However, only about thirty percent 
of these sites end up being occupied, with the remaining sites believed to be blocked by 
the protein folding process which is occurring at the same time92. Immediately, the three 
glucose residues and one mannose residue are removed, each by a different glycosidase. 
It is thought that the glucose residues serve as a signal to indicate that the oligosaccharide 
is ready for transfer to the protein as well as to indicate that the protein has achieved 
proper folding and is ready for transport to the cis Golgi92. The glycoprotein will be 
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further processed in the ER and Golgi apparatus; however the pentasaccharide "core" of 
two GlcNAc and 3 mannose residues is common to all N-linked glycans. The 
glycopeptide will then be transported to the cis Golgi where it will be further modified. 
For example, secretory or plasma membrane proteins will lose an additional three 
mannose residues. Typically while in the medial Golgi, two more mannoses are 
removed, followed by the addition of two GlcNAc and one fucose residues. Finally, the 
glycoprotein will receive one GlcNAc, one galactose, and one sialic acid while in the 
trans Golgi92. The complexity and structure of N-linked carbohydrates is determined 
both by the sequence and conformation of the protein itself as well as the type of 
glycosyltransferases present in the Golgi during the glycosylation process. N-linked 
glycans are typically branched and can be highly decorated. By the time the protein 
reaches the trans Golgi, it will be completely modified and ready for transport. In disease 
states, it is believed that the great biodiversity of both glycosyltransferases and 
glycosidases present in the vertebrate Golgi are responsible for alteration of "normal" 
glycosylation patterns92. 
The Carbohydrate-Cancer Connection 
Cancer progression has several stages including proliferation, invasion, 
angiogenesis, metastasis, and immunity; all of which may be affected by a number of 
glycoconjugates as indicated by innumerous published studies ' " . The first stage, 
tumor proliferation, begins with the deregulation of the cell cycle by a disruption in the 
balance of tumor suppressors and oncogenes. Correlations between tumor proliferation 
and carbohydrates have been difficult to determine, however it seems that glycoproteins 
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and glycolipids most commonly play a role in this stage of cancer progression. For 
example, N-linked glycosylation of the insulin-like growth factor 1 receptor (IGF1R) has 
been shown to necessitate the phosphorylation and translocation of IGF1R, therefore 
leading to growth and survival of melanoma and sarcoma cells96. In addition, extensive 
studies have shown the role of mucins and other O-linked glycans in the role of tumor 
proliferation97"99. The mucin MUC4 gene has been shown to be over-expressed on the 
surface of mammary tumor cells as compared to normal mammary epithelium100. MUC4 
is responsible for the up-regulation of the epidermal growth factor (EGF) receptor 
ERBB2, which then aids in the inhibition of apoptosis, a common occurrence in tumor 
proliferation . 
After tumor cells begin to proliferate and the tumor continues to grow, the 
peripheral cells then begin to detach from each other and from the extracellular matrix, 
where they then invade and migrate through adjacent tissue. This invasion process 
requires many factors, including the alteration of cell-surface receptors and their ligands, 
as well as proteases and glycosidases to degrade the extracellular matrix. These changes 
require the aid of glycoconjugates such as N-linked and O-linked glycoproteins, and 
proteoglycans. For example, increased sialylation has been shown to play a vital role in 
tumor invasion, likely due to the highly negative nature of sialylated glycoforms which 
may aid in the cellular detachment stage93'101. Once tumor cells begin to rapidly grow 
and spread, they need additional nutrients and therefore must create their own vasculature 
to supply such nutrients, a process known as tumor angiogenesis. Heparan sulfate 
proteoglycans are the most commonly seen glycoconjugates involved in tumor 
angiogenesis. Certain pro-angiogenic factors, such as vascular epithelial growth factor 
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(VEGF), interleukin-8 (IL-8), and platelet-derived growth factor (PDGF) to name a few, 
bind heparan sulfate102, indicating a correlation between these proteoglycans and tumor 
angiogenesis. 
The next stage in cancer progression involves the movement of tumor aggregates 
to distant organs, also known as metastasis. Selectins are cell-surface receptors 
responsible for cell-cell adhesions which are involved in tumor metastasis. Their ligands 
often carry O-linked oligosaccharides decorated with sialic acid, fucose, and sulfate92'93. 
Examples of these ligands are the Lewis type blood group antigens, specifically sialyl 
Lewis X (SLex) and sialyl Lewis A (SLeA), which are shown to be over-expressed on 
tumor cells as compared to their normal cellular counterparts for lung, colon, gastric, and 
pancreatic cancers93'103"105. CA19-9 is a sialyl Lewis A serum tumor biomarker which is 
used to detect many gastrointestinal cancers. However, there are many false positives 
using this serum test, as CA19-9 will sometimes also recognize certain inflammatory 
states of the aforementioned tissues . Specific to prostate cancer, cancerous cells have a 
tendency to metastasize to bone, and it is thought that E-selectin with the aid of sialyl 
Lewis X is responsible for the binding of circulating prostate tumor cells to the bone 
marrow endothelial cells107. The final stages of cancer progression involve the alteration 
of host immunity, which allows the tumor to continue to grow and spread throughout the 
host organism. While little is known about the role of glycosylation in this final stage, 
some studies have shown that certain glycosphingolipids and O-linked glycoproteins may 
be involved in immune silencing, allowing the tumor to evade the cytotoxic effects of the 
host immune system93,108. 
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Due to the widely-seen involvement of glycosylation in various cancer systems, it 
is likely that altered glycosylation states are involved in prostate cancer progression as 
well, and that these changes can be detected by mass spectrometry-based strategies. A 
few reports have shown that the overexpression of O-glycosylated mucins are involved in 
prostate cancer progression109"111, while others have associated altered N-glycosylation 
patterns with prostate cancer, either globally112, or protein-specifically113,114. In 
particular, the glycosylation of PSMA was studied in prostate cancer tissues, serum, and 
metastatic cell lines (LNCaP), indicating the presence of complex N-linked glycans on in 
vivo sources of PSMA, and high mannose N-glycans on PSMA from immortalized cell 
lines113. 
PSA glycosylation 
Previous studies on PSA glycosylation have compared seminal plasma from 
healthy donors to prostate tumor metastatic cell line LNCaP115"117, as well as normal 
seminal plasma to prostate cancer and BPH sera118. PSA contains 8% carbohydrates by 
mass119, and has one glycosylation site at asparagine (Asn)-45120. The structure of this 
glycan has been previously reported to be of either high-mannose subtype121 or a 
complex sub-type with frequent sialylation, core fucosylation, and a number of terminal 
N-acetylgalactosamines (GalNAc) when purified from healthy seminal plasma 
samples117. PSA glycans isolated from LNCaP cell lines have also been characterized as 
having some triantennary structures116, as well as decreased sialic acid content and the 
presence of increased fucose and GalNAc content115. Because of advances in the PSA 
serum test which include the comparison of different forms of PSA, a recent study was 
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completed that monitored the presence of sialic acid monosaccharides on free and 
proPSA in serum, seminal plasma and tissues from both healthy and prostate cancer 
patients122. This study did not detect any significant differences in sialylation among the 
different groups or sample sets122. A second study compared free and complexed PSA 
glycans derived from serum, concluding that the glycans from both forms of PSA were 
primarily sialylated and fucosylated biantennary structures123. Although less prevalent, 
the presence of a few multiantennary complex structures were detected as well123. 
However, for the aforementioned studies, the specific composition and anomeric 
structural configurations for each oligosaccharide isolated were not determined, and these 
studies involved analysis of samples obtained from very few clinical samples. 
PAP glycosylation 
PAP has three glycosylation sites at Asn-62, Asn-188, and Asn-301124'125, making 
it a more difficult target for site specific structural characterization, yet one that may be a 
suitable complement to PSA. Earlier X-ray crystallography of PAP from normal seminal 
plasma has found the Asn-62 and Asn-301 glycan modifications consisted of primarily 
high mannose oligosaccharides, while glycans at Asn-188 had more complex structures 
containing sialic acid and fucose124. In relation to cancer, one study involving lectin 
analysis of PAP derived from tissue in BPH and prostate cancer patients found evidence 
of a decrease in the high mannose chains of Asn-62 and Asn-301, as well as an increase 
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of non-fucosylated hybrid structures in prostate cancer as compared to BPH . Similar 
to the studies on PSA glycosylation, these studies on PAP oligosaccharide content lack in 
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detailed structural information, and include low numbers of clinical samples used for 
each study. 
1.3 Proximal Fluids of the Prostate for Biomarker Discovery 
Proximal fluids are defined as any fluid found adjacent to a given tissue. It is 
currently understood that proximal fluids are a great source for biomarker discovery126, 
with seminal plasma and expressed-prostatic secretion (EPS) fluids both being proximal 
to the prostate. In addition, PSA and PAP protein concentrations are much higher in both 
seminal plasma and EPS fluids relative to blood127, allowing for enhanced purification, 
detection, and analysis of these biomarkers. Seminal plasma consists of fluids originating 
not only from the prostate, but also from several other male accessory glands such as the 
seminal vesicles, epididymis, and Cowper's gland128. Seminal fluid has been used in 
research and the clinic for many purposes outside of the cancer realm, and has also been 
analyzed in several studies for biomarker purposes related to both prostate and testicular 
cancers128"130. Clinically, the term "expressed" is used to describe the process of 
manually squeezing a gland, which results in fluid being expelled and subsequently 
collected. EPS represents the fluid being secreted by the prostate following a prostate 
massage, which in turn is excreted via the urethra alone or with urine. This fluid is 
commonly collected in the clinic to examine chronic prostatitis and inflammatory chronic 
pelvic pain syndrome131. In addition, the cellular sediment obtained from EPS fluids is 
currently being used for prostate cell-associated PCA3 mRNA testing (Gen-Probe Inc, 
San Diego, CA). These studies aim to develop a genetic based clinical assay by using the 
mRNA levels of PCA3 as a marker for prostate cancer74'132134. Using these EPS fluids 
21 
for protein-based biomarker discovery or in the clinic for biomarker screening has yet to 
gain popularity. Because these fluids should be enriched for prostatic proteins that may 
be difficult to detect in serum, it seems likely that they have high utility in the clinic for 
the screening and potential staging of prostate cancer. 
1.4 Proteomics, Glycomics and the Advances of Mass Spectrometry 
With the completion of the Human Genome Project in 2001135, researchers began 
focusing on the next level of discovery, that of the human proteome as well as proteomes 
of many other species. The term "proteome" was first coined in 1994136 and was initially 
defined as the protein complement to the genome, with "proteomics" being defined as the 
study of protein structure and function in a specific sample (i.e. tissue, cell, or bodily 
fluid) at a specific time. While the human genome is complex, the complementing 
proteome contains even more information, due to the fact that individual genes can give 
rise to many different proteins and isoforms of a protein. These protein profiles may be 
altered due to the physiological and pathological states at a given time in a given subject, 
and commonly, post-translational modifications are responsible for differing disease 
phenotypes137. Due to these factors, it is possible to detect a protein-based biomarker that 
can differentiate between healthy and diseased states for many conditions, including 
cancer. 
Two-Dimensional Electrophoresis 
Two-dimensional electrophoresis (2DE) was and is still used today for initial 
sample separation for proteomics analyses. This separation methodology as applied to 
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proteins relies on two independent parameters that are functional properties of all 
proteins: 1) their molecular mass and 2) their isoelectric point (pi), the pH at which the 
net charge of each protein is zero. The pi of a protein is a property unique to each protein 
dependent on the total number of positively and negatively charged constituent amino 
acids. At a pH above the pi, a protein carries a net negative charge, and at a pH below 
the pi, a protein carries a net positive charge. These same properties also allow 2DE to 
separate proteins based on their post-translational modifications (i.e. glycosylation), 
particularly if these modifications are charged or have substantial mass. For most 
applications, the first dimension for 2DE is an isoelectrofocusing (IEF) step, followed by 
a conventional sodium dodecyl sulfate (SDS)-polyacrylamide gel separation based on 
molecular mass in the second dimension. The fundamental aspects of the most 
commonly used approaches of 2DE for protein separations were reported independently 
by Klose138 and O'Farrell139 in 1975. Original innovations in isoelectric focusing relied 
on the inclusion of multi-charged chemicals termed ampholytes, that when placed in an 
electric field would generate and align the ampholyte molecules into a pH gradient. 
Originally, this was accomplished by combining the ampholytes with acrylamide, and 
then polymerizing these solutions in glass tubes (referred to commonly as "tube gels"). 
While this was an effective way to perform IEF separations of proteins, the method 
required specialized equipment and was difficult to reproduce gel to gel. A major 
improvement in IEF was originally reported in 1982 by Bjellqvist et al.140, who reported 
the creation of immobilized pH gradient (IPG) strips. Ampholyte molecules were 
replaced by acidic and basic acrylamido derivatives that are co-formed with acrylamide 
gel polymerization on plastic backed strips; hence, the tube gels have been replaced by 
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these IPG plastic strips. These improvements in the IEF component of 2DE have driven 
increased use of this approach in proteomics. It is necessary to keep in consideration how 
the samples will be analyzed post-2DE. Protease inhibitors play an important role in 
maintaining the integrity of a sample's proteome; however some, such as 
phenylmethylsulfonyl fluoride (PMSF), can interfere with downstream analysis, such as 
tryptic digestion. Depending on the complexity of the sample(s) being analyzed, there 
may be too many spots to effectively compare and analyze with the human eye. Thus, 
there are various analysis programs available that can compare spots between gels. These 
programs are based on manually selecting a certain number of consistent landmarks 
between the gels to be analyzed, from which the software can then align the gels and 
determine any differential spots. Consequently, the most critical step of these analyses is 
spot detection and quantification. Alternatively, 2D gels can be transferred to a 
membrane such as PVDF for immunoblotting. At this point, proteins of interest can be 
detected by following a standard western blotting protocol, making this method useful 
when wanting to quickly visualize the possible multiple isoforms of one protein. 
Development of Protein Sequencing Methods 
After a decade of study, insulin was the first protein to be completely structurally 
characterized in 1954. This mammoth task was achieved by Frederick Sanger and his 
colleagues using a method termed the dinitrophenyl group-labeling (DNP) method, which 
covalently modifies the terminal amino acid in a peptide141. This DNP group gives the 
peptide a distinctive yellow color which allows for visualization using two-dimensional 
paper chromatography. In addition, the DNP group makes the derivatized amino acid 
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resistant to acid hydrolysis. In order to get a contiguous sequence, the sample was first 
fully hydrolyzed, and then sequential partial hydrolysis reactions were performed, 
allowing for larger and larger peptide fragments with overlapping sequence information. 
In concert with the DNP labeling method, partition (filter paper) chromatography, 
developed by AJ.P. Martin and R.L.M. Synge in 1952, allows for the separation of the 
amino acids and peptides and was the basis for modern chromatography separation 
techniques142. 
The year 1930 saw the first successful stepwise degradation of peptides 
performed by Abderhalden and Brockmann using phenylisocyanate (PIC)143. However, it 
wasn't until Pehr Victor Edman altered the method and begun using pheylisothiocyanate 
(PITC) as a coupling reagent that the method gained popularity. The change in the 
reagent allowed for a more easily cleaved labeled amino acid, therefore allowing for 
more successful analysis. Today's amino-terminal sequencing methods are all based on 
the Edman degradation procedure144. Edman degradation comprises of three steps. The 
first step is the coupling reaction where the free amino-terminal amino acid is labeled 
with PITC which forms a phenylthiocarbamyl (PTC) polypeptide. It is noteworthy that 
polypeptides that are modified at the amino terminal cannot be coupled with the PITC. 
The second step involves cleavage of the PTC-amino acid by acid hydrolysis creating an 
anilinothiazolinone (ATZ) amino acid. This step also results in a shortened polypeptide 
which can then be used for subsequent coupling and cleavage in repetitive cycles. The 
third and final step of Edman degradation involves conversion of the unstable ATZ 
amino acid into a more stable phenylthiohydrantoin (PTH) derivative. Finally the 
derivatized amino acids are sequentially identified using HPLC. Automation of this 
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procedure was first performed in 1967 which automated the coupling and cleavage steps 
and allowed researchers to routinely identify the sequence of the first 30-40 amino acids 
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in a given protein ' 
History of Mass Spectrometry 
While the Edman degradation method has been revamped and utilized for many years, 
the advances in mass spectrometry have almost but all replaced this protein sequencing 
method. Mass spectrometry based techniques are much more sensitive, can handle 
complex protein mixtures, and can be used in a more high-throughput manner. The idea 
of mass spectrometry dates back to 1897 when J.J. Thomson discovered electrons using 
cathode rays. He observed that the ions in the gaseous phase moved through the cathode 
ray tubes in a trajectory that were proportional to their "mass-to-charge" (m/z) ratios142. 
Based on his discovery, the first mass spectrometer called a parabola spectrograph was 
conceived. Over the decades more sophisticated instruments were developed. The first 
time-of-flight (TOF) analyzer was developed in 1946 by W.F. Stephens, with Wolfgang 
Paul creating the first quadrupole mass analyzer in the mid 1950's. Paul also created the 
first quadrupole ion trap, and the ion trap first became available commercially in 1983147. 
Currently, TOF, quadrupole, and quadrupole ion trap technologies are the most widely 
used mass analyzers in mass spectrometry laboratories147. All mass spectrometers have 
four basic components: an ionization source, a mass analyzer, a mass detector, and a data 
processor (Figure 4). The ionization source is responsible for converting the analytes 
from either their solid or liquid states into gaseous-phase ions. These ions are then 

















Figure 4. Components of a mass spectrometer. After the sample is introduced to the 
ionization source, the analytes are converted from either their solid or liquid states into 
gaseous-phase ions by the ionization source. The mass analyzer will then separate the 
ions by either electric or magnetic fields. The ions will then strike the detector 
individually based on their m/z value as they leave the mass analyzer. Finally, the data 
processor supplies the visual output of analyte information, showing both the m/z value 
and the relative abundance of each ion measured by the detector. Adapted from Simpson, 
2003. 
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magnetic fields, which are commonly observed as a function of time. After traveling 
through the mass analyzer, the ions will strike the detector one at a time, based on their 
m/z value. The data processor is responsible for the visual output of analyte information, 
indicating both the m/z value and the relative abundance of each ion measured by the 
detector142. 
Soft Ionization Mass Spectrometry 
Fast atom bombardment ionization (FAB) was developed in the early 1980s148'149 
and was the first soft-ionization mass spectrometry technique available for use with 
proteins and peptides142. This technology works by dissolving the analyte (i.e. protein or 
peptide) in a nonvolatile liquid matrix (i.e. glycerol), which is then placed under vacuum 
in the instrument. Next, the sample-matrix mixture will be bombarded with a flow of 
fast-moving neutral atoms. These atoms usually derive from ionization of argon, and are 
used to change the analyte ions into a gaseous phase. This method allows for the analysis 
of ions that are 10,000 daltons or greater. Thus, this method is not optimal for small 
peptide fragments, or other small biochemical molecules. 
For some instruments, a matrix is needed to help the analyte (sample) ionize and 
travel to the mass detector. Matrix-assisted laser desorption/ionization (MALDI) begins 
with the mixture of matrix and analyte. MALDI was first developed in 1988 by Karas 
and Hillenkamp150. Matrices are acidic compounds which can be absorbed at different 
laser wavelengths, usually UV337nm- The matrix is typically applied to the analyte in 
1000-fold concentration142. For glycopeptide and glycan analyses, typically 2,5-
dihydroxybenzoic acid (2,5-DHB) is used, as it is best at stabilizing the sialic acids on 
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acidic glycans. The analyte-matrix mixture is then applied as a few microliters to a target 
plate, where the plate itself can have different chemistries. The sample and matrix are 
allowed to co-crystallize prior to entering the instrument. Energy in the form of a pulsed 
UV laser is applied to the spot with the crystallized sample-matrix. The ions will excite 
and be desorbed from the solid matrix mixture and the matrix helps stabilize the singly-
charged ions as they travel through a strong electric field, then through the TOF, and 
finally to the mass detector. The TOF mass analyzer will measure the m/z values of the 
analytes, which is calculated based on the time it takes for a specific ion to travel a set 
distance and strike the detector142. 
Another soft-ionization technology termed electrospray ionization (ESI) was first 
developed in 1989 by Fenn et al151. Samples in a liquid phase (typically organic) are hit 
with a high-voltage potential as they are passed through a small capillary tube. The ions 
are then desorbed into the gaseous phase and rapidly evaporate into charged droplets. 
This process occurs due to both high heat and a strong electric field present at the tip of 
the capillary tube. From here, the samples will enter the mass analyzer, which is 
typically either an ion trap or a quadrupole. Unique to ESI, singly and multiply charged 
ions can arise from a single precursor ion as they travel out of the capillary and to the 
mass analyzer. This feature allows larger molecules (> 10,000 daltons) to be accurately 
evaluated by a mass analyzer such as the quadrupole or ion trap which typically have a 
limit of detection of 10,000 daltons. The number of charges an ion may carry as it 
evaporates off of the capillary is dependent on factors such as the voltage potential, the 
solvent pH and composition, and the analyte itself142. Fortunately, a high-resolving 
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instrument is capable of determining the charge state in addition to the mass of a given 
ion, providing the user with even more valuable data. 
Tandem Mass Spectrometry and Liquid Chromatography Coupled to Tandem 
Mass Spectrometry 
As a mass spectrometer first scans and detects the ions coming from the analyte, 
these initial spectra are full MS scans, representing parent ions. These intact parent ions 
can provide information all on their own, however even more information can be 
obtained by fragmentation of the parent ions. This secondary analysis is referred to as 
tandem MS, MS/MS, or MS". Fragmentation studies will offer structural information of 
the compound being analyzed. Most commercially available mass spectrometers using 
soft ionization are capable of tandem MS. A precursor (parent) ion is selected from the 
initial stage of analysis, an intermediate reaction event occurs, the resulting "product 
ions" are analyzed142. In the case of MS", these secondary stages are repeated 
consecutively on individual ion peaks until all information desired has been obtained. 
The intermediate reaction events are where the precursor ions are fragmented into 
product ions. These events require a source of high energy which varies based on the 
type of instrument being used, as well as the type of analyte being fragmented. The most 
common form of energy used is collision-induced dissociation (CID), which involves the 
use of an inert gas (i.e. helium or argon) to excite the ions and cause them to break apart. 
There are two categories of tandem mass spectrometers. The first involves a 
tandem-in-space instrument which has multiple mass analyzers in tandem, each 
responsible for a specific set of analyses142. Examples of such instruments include 
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MALDI-TOF/TOF, triple quadrupole instruments, and hybrid mass spectrometers. The 
second category includes a tandem-in-time instrument that has only one mass analyzer, 
allowing for the tandem analyses to take place in the same analyzer; however the events 
are separated in time142. Examples of these types of tandem instruments include 
quadrupole ion trap analyzers coupled with either MALDI or ESI, and Fourier transform-
ion cyclotron resonance (FT-ICR). 
Numerous mass spectrometer instruments today work in conjunction with liquid 
chromatography (LC) systems, and these types of systems are commonly referred to as 
LC-MS/MS. These on-line systems allow for analyte separation prior to entry into the 
mass spectrometer, thus allowing for more in-depth analyses of a given sample. They 
also allow for gel-independent separation of highly complex peptide mixtures, which was 
first demonstrated by Hunt et al. in 1992136'152. Most of these separations are achieved 
using reversed-phase high-performance liquid chromatography (RP-HPLC) coupled to 
ESI. This separation allows for complex mixtures to be applied to a mass spectrometer 
(i.e. seminal plasma or EPS fluids) without losing any protein or peptide information. To 
further improve the sensitivity of the MS/MS analysis, capillary columns can be utilized 
with this type of LC being referred to as nano-LC. These differ from traditional HPLC 
columns by being narrower, therefore slowing down the flow rate and also by functioning 
as the ionization source (i.e. nanospray ionization or NSI). This will also further 
concentrate the sample before it is sprayed into the mass spectrometer142. 
Protein Identification by Mass Spectrometry 
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The emergence of protein databases began in the late 1970's and early 1980's as a 
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result of the effectiveness of 2-DE protein profiles . Computer software programs 
capable of subtractive pattern analysis, clustering algorithms, and multivariate statistics 
were developed to complement these databases, allowing for further characterization of 
proteins isolated by 2-DE136,154"157. These early databases and software programs were 
never fully implemented due to the complexity of 2-DE analysis, as well as the growing 
popularity of soft ionization techniques in the late 1980's, causing for a surge of protein 
identification methods based on mass spectrometer analysis in the early 1990's136'158. 
Two main methods came from this decade: peptide mass finger printing (PMF) and 
tandem mass spectrometry. The first, PMF, is also known as peptide mapping or peptide 
mass mapping, and relies on a list of experimental peptide masses matching up to the 
calculated list of all peptide masses of a each protein entry in a given database, thus 
resulting in protein identification136. Five groups separately, yet nearly concurrently, 
developed computer software capable of protein identification by PMF159"163. The PMF 
method is regularly used to identify gel-separated proteins, and almost universally used in 
conjunction with MALDI-TOF mass spectrometers136. The second protein identification 
method utilizes tandem mass spectrometry by analyzing the fragmentation spectra and 
comparing it against a given database search engine using a mathematical algorithm, such 
as SEQUEST164 or MASCOT, which can also be used for PMF searches165. These two 
protein identification methods are still the most widely used today in proteomic studies 
today. The abovementioned search engines are used in conjunction with publically 
available sequence databases. Both protein sequence databases164'166, as well as the 
human genome library135'167 have been established, with new protein sequences 
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constantly being added, thus allowing for on-going improvement to the accuracy of 
peptide searches. 
Carbohydrate Structural Analysis by Mass Spectrometry 
In 1988, Rademacher, Parekh, and Dwek first coined the term "glycobiology", 
with the intention for the term to highlight the marriage of traditional carbohydrate 
chemistry and biochemistry disciplines to the modern cellular and molecular biology 
disciplines of glycans92. Today, the study of oligosaccharide, or glycan, structure and 
function can also be identified as glycomics. The term glycan is used to describe a chain 
of sugars, whether they be linear or branched. 
Historically, structural N-glycan analysis is performed with the use of 
exoglycosidases and gel filtration chromatography, HPLC, or MALDI-MS168. Full 
characterization of a given glycan molecule entails analysis of monosaccharide 
composition, sequence, branching, linkage, and anomericity of said glycan169. However, 
obtaining all of the above information is difficult and tedious. The use of 
exoglycosidases and tandem MS are what allow for the elucidation of glycan structure 
and linkage. Exoglycosidases are enzymes with specificity for certain monosaccharides 
and in some cases, certain glycosidic bonds. For example, neuraminidase will only 
remove terminal sialic acids. The loss of the monosaccharide from the entire moiety is 
then monitored by the abovementioned methods. This stepwise process may be tedious 
and requires the availability of a wide range of exoglycosidases; however the end result is 
a complete structural determination of the glycan of interest. While this protocol was 
traditionally only applied to N-glycan analysis, it is commonly used for O-glycan 
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analysis as well170. Most recently, the advances in mass spectrometers have allowed 
researchers to bypass the exoglycosidase steps and rely solely on MS/MS fragmentation 
data to analyze N-glycan structural information. Fast atom bombardment (FAB) mass 
spectrometry was the forefather in this type of analysis, but has been replaced by more 
sensitive technologies like ESI or MALDI ionization168. 
A second aspect of glycan analysis requires the cleavage of the intact 
oligosaccharide from the protein or peptide, which can be achieved by either chemical or 
enzymatic reactions. The chemical method typically relies on hydrazine, which will 
destroy any protein or peptide information, however it quickly and easily results in a 
cleaved glycan prepared for further analysis. Endoglycosidases are enzymes which will 
cleave N-linked oligosaccharides from proteins and peptides, and include two different 
types of cleavage. Enzymes such as Endo F and Endo H (both favor cleavage of high-
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mannose types) , and Endo D (cleavage of complex glycans) cleave between the two 
core GlcNAc residues, therefore leaving the first GlcNAc residue attached to the 
protein . Alternatively, PNGase A (purified from almonds, cleaves both high-mannose 
and complex glycans)172 and PNGase F remove the entire oligosaccharide cleaving 
between the first GlcNAc and the asparagine residues, and as a result, these enzymes are 
termed peptide ./V-glycosidases. The most popular enzyme today for removing an entire 
N-linked glycan from the protein is PNGase F (Peptide-N4-(acetyl-6-glucosaminyl)-
asparagine amidase)173. PNGase F gained its popularity because it is capable of 
hydrolyzing all types of N-glycans, including high-mannose, hybrid, and bi-, tri-, and 
tetraantennary structures in a rapid manner173. PNGase F is purified from 
Flavobacterium meningosepticum, and recognizes the tripeptide N-glycosylation signal, 
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cleaving the covalent linkage between the asparagine residue and the first GlcNAc; as 
long as there is not a core a-(l-3)-linked fucose present. This modification doesn't seem 
to present a problem with mammalian-derived samples whose N-linked glycopeptides 
carry core fucoses with an a-(l-6) linkage. In addition to the removal of the intact N-
glycan by PNGase F, the enzymatic cleavage reaction results in conversion of the 
asparagine residue to an aspartic acid residue. This alteration allows for additional 
analysis of the peptide portion of the glycopeptide. N-linked glycosylation sites that are 
truly occupied can be identified by first incubating a peptide mixture with PNGase F 
followed by capture of the deglycosylated peptides and mass spectrometry analysis of the 
peptides by either MALDI or ESI and a protein database search specific for the 
deamidation modification (one dalton mass difference) to the peptide174. The resultant 
intact N-glycans from PNGase F digestions can be analyzed directly by mass 
spectrometry, or they can first be derivatized by either the addition of a fluorescent label 
(i.e. 2-Aminobenzoic acid, 2-AA; 2-Aminobenzamide, 2-AB) or by chemical 
modification (i.e. permethylation). Underivatized glycans are less stable and therefore 
more likely to fragment in full MS scans, thus complicating the subsequent structural 
analysis. 
Glycopeptide analysis is widely used today in glycomic studies; however the 
properties of glycosylated peptides pose problems in mass spectrometry analyses. The 
two main issues are due to the fact that protein glycosylation is very heterogeneous, and 
that glycopeptides typically do not ionize as well as their nonglycosylated counterparts, 
and therefore these peaks are often suppressed. Despite these complications, both 
MALDI and ESI soft ionization techniques are capable of analyzing the carbohydrate 
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structures attached to the peptides, especially when used in a tandem mass spectrometry 
mode. MALDI is more commonly used for glycan identification and structural 
determination, while ESI is better at obtaining more detailed structural and linkage 
information175. For some analyses, determining the peptide sequence is as important as 
identifying the glycan sequence. With traditional high energy MS/MS like collision 
induced dissociation (CID), the glycan structure will fragment primary to the peptide 
backbone, thus not providing much peptide information176. Fourier transform ion 
cyclotron resonance mass spectrometry (FT-ICR-MS) allows for MS/MS analysis 
providing very high mass accuracy and mass resolution and ultimately definite protein 
identification177. One soft fragmentation method unique to FT-ICR-MS/MS is electron-
capture dissociation (ECD). This method will cleave the peptide backbone without 
disrupting the post-translational modifications (PTM), therefore allowing for significant 
sequence coverage, including the localization of the PTM, such as N- and O-linked 
17S 17R 170 
glycosylation . In addition, this technique is gentle enough to analyze highly 
sialylated structures without premature loss of terminal sialic acids180, which allows for 
more accurate N-linked oligosaccharide structural identification. Additionally, electron 
transfer dissociation (ETD) is a soft fragmentation method similar to ECD, and is 
performed in quadrupole ion trap mass spectrometers181. This method also cleaves the 
peptide backbone in such a manner to provide sequence and PTM linkage site 
information, indicating the utility of this fragmentation platform in glycoproteomic 
approaches182. Whether studying intact glycopeptides or cleaved glycans, it is commonly 
necessary to desalt the sample and remove organic contaminants prior to mass 
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spectrometry analyses, which can be achieved by using column chromatography with 
resins such as AG-3, AG-50, CI8, and graphitized carbon ' 
Finally, when analyzing either glycans or glycopeptides one can either isolate a 
single, purified protein as a target, or alternatively, global analysis of glycans from a 
given cell type, tissue, or fluid can be performed. Global glycomic analysis can provide 
an abundance of information, once its limitations have been addressed. As with 
proteomic analyses, the dynamic range of a given biological sample can make mass 
spectrometry analyses very difficult. One way to overcome this challenge is to utilize 
enrichment techniques such as affinity chromatography, with the most common being 
lectin affinity chromatography. Lectins are proteins which specifically bind 
monosaccharides, therefore separating out glycoconjugates in a particular sample from 
other non-glycosylated molecules. Additionally, if the starting sample material contains 
highly abundant proteins that are not of interest (i.e. albumin), then commercially 
available kits can be used to remove these contaminating proteins from the given sample, 
thus decreasing the dynamic range of the fluid, and increasing the concentration of the 
lower abundant targets. Further fractionation of the sample by an online-LC system will 




DISSERTATION RATIONALE AND SUMMARY OF AIMS 
The goal of this research project is to examine the N-glycosylation patterns of 
prostate specific antigen (PSA) and prostatic acid phosphatase (PAP) in prostate proximal 
fluids, as well as to examine the total glycan profile for prostate proximal fluids with the 
intent of discovering carbohydrate-based biomarkers for the detection of early prostate 
carcinomas. 
Currently, serum PSA is the "gold standard" protein biomarker used in the clinic 
for detecting and diagnosing prostate cancer. However, serum PSA levels can be 
elevated in non-cancerous conditions as well, such as benign prostatic hyperplasia. This 
overlap causes many unnecessary biopsies, radical prostatectomies, and patient anguish. 
While other clinical measures are taken into consideration for a more accurate diagnosis, 
there is still a great need for better clinical detection methodologies for prostate cancer, 
including improved biomarkers. Therefore, the specific hypothesis of this dissertation 
is that characterization of the N-linked carbohydrates attached to known prostate-
derived proteins as well as the N-linked carbohydrates present in prostate-derived 
fluids will allow for the discovery of new clinically-relevant biomarkers for the 
detection and diagnosis of prostate carcinomas. The specific hypothesis will be tested 
by creating disease-defined pools of prostate-derived samples, which will be used in 
proteomic and glycomic-based assays utilizing mass spectrometry for the detection of 
both glycopeptides and cleaved carbohydrates. 
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Initial glycomic and proteomic studies will be completed using seminal plasma 
samples, pools of which were created based on their disease status: normal, BPH, or 
prostate cancer. These samples will provide ample protein levels of both PSA and PAP 
for glycopeptide and glycomic analyses which will add to current knowledge of PSA and 
PAP glycosylation. In addition to this sample set, pools of disease-defined expressed 
prostatic secretions (EPS) will be generated and subsequently analyzed for detection of 
both protein levels and carbohydrate structures of PSA and PAP, as well as examined for 
their total glycomic profile. Because EPS fluids are more readily collected in the clinic, 
we believe these samples can be used not only for discovery of cancer biomarkers, but 
also for their validation and applications in future clinical assays. 
The hypothesis of this dissertation was evaluated by addressing the following 
specific aims: 
Aim I. Develop methodologies for the characterization of N-linked glycans of prostate-
specific antigen and prostatic acid phosphatase in seminal fluids. This aim entails: 
A. Generating sample sets and fractionation of pools in order to obtain purified 
forms of prostate specific antigen and prostatic acid phosphatase. Protein content and 
quality will be examined by immunoblotting and MALDI-TOF mass spectrometry. 
B. Analysis of PAP glycopeptides by hybrid triple quadrupole/linear ion trap 
mass spectrometry in order to better understand which subtypes of carbohydrates are 
attached at each N-linked glycosylation site for PAP in seminal plasma samples. 
C. Permethylation of cleaved N-linked carbohydrates attached to both PSA and 
PAP and analysis of the derivatized structures by MALDI-TOF mass spectrometry. 
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Aim II. Establish expressed prostatic secretions as a source of prostate specific antigen 
and prostatic acid phosphatase. This aim entails: 
A. Collection and preparation of EPS samples for protein-based assays. Both 
individual and pooled sample sets will be utilized for the detection of both PSA and PAP. 
B. Detection of PSA and PAP in individual samples by LC-ESI mass 
spectrometry in order to compare a common urine collection to an EPS urine collection 
for the presence of prostate-derived proteins. Additionally, an individual direct EPS 
sample will also be analyzed by LC-ESI mass spectrometry for the presence of PSA and 
PAP and other prostate-derived proteins. 
C. Two-dimensional PAGE analysis and comparison of a urine sample to an EPS 
urine sample in order to visualize the different protein patterns between these two types 
of fluid collections. 
D. Two-dimensional PAGE and immunoblotting analysis of pooled EPS urine 
samples for the detection of both PSA and PAP. The ability to visualize the various 
isoforms of PSA and PAP in these fluids will allow for further proteomic and glycomic 
analyses. 
E. Enzyme-linked immunosorbent assay analysis of PSA and PAP concentrations 
in individual EPS urine and direct EPS samples. Determining PSA and PAP levels in 
these proximal fluids will aid in determining the value of expressed prostatic secretions 
as a source of protein-based biomarkers for evaluating prostatic diseases. 
Aim III. Application of new methodologies to expressed prostatic secretions for prostate 
cancer glycoprotein biomarker discovery. This aim entails: 
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A. Generation of EPS urine and direct EPS pools based on disease stratification. 
These pools will be concentrated by centrifugal filtration, allowing for enrichment of 
targeted glycoproteins. The protein pools will be used for the purification of PSA and 
PAP for N-linked glycosylation analysis, as well as for total N-linked glycan analysis by 
mass spectrometry. 
B. Permethylation of cleaved N-linked carbohydrates attached to both PSA and 
PAP and analysis of the resulting derivatized structures by MALDI-TOF mass 
spectrometry. Parent masses will be assigned a biologically relevant carbohydrate 
structure determined by database searches, and the total structures identified will be 
catalogued. 
C. Analysis of PAP glycopeptides by hybrid triple quadrupole/linear ion trap 
mass spectrometry in order to better understand which subtypes of carbohydrates are 
attached at each N-linked glycosylation site for PAP in EPS urine fluids. Both tryptic 
and chymotryptic digestions will be utilized in order to obtain more complete coverage of 
the N-linked glycopeptides and their corresponding N-glycan structures. 
D. Total glycan analysis of permethylated cleaved N-glycans for both EPS urine 
and direct EPS fluids by MALDI-TOF/TOF. Disease-defined pools will be compared for 
their N-glycan profile, with the intention of determining any differences among disease 
states which can be used in future carbohydrate-targeted assays. 
E. Computational data analysis of MALDI-TOF spectra using Clinprot software. 
Peak intensities of disease-defined pools will be compared to determine if there are any 
glycan differences among the sample cohorts. 
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In summary, the above Specific Aims will aid in the discovery of carbohydrate 
targets for new clinical markers of prostate carcinoma diagnosis and prognosis. Due to 
the close link between altered glycosylation and cancer, it is likely that a number of 
changes occur to the N-l inked glycans of prostate-derived proteins, all of which should be 
detectible with the above glycoproteomic and glycomic platforms. Following discovery 
of any N-linked glycosylation alterations present, the target carbohydrates can then be 
used in validation assays and subsequently in high-throughput clinical assays. These 
tests would utilize the clinically relevant EPS fluids and a multi-well plate platform in 
order to allow for rapid results. 
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CHAPTER III 
AIM I: DEVELOP METHODOLOGIES FOR THE CHARACTERIZATION OF 
N-LINKED GLYCANS OF PROSTATE-SPECIFIC ANTIGEN AND PROSTATIC 
ACD3 PHOSPHATASE IN SEMINAL FLUIDS 
4.1 Introduction 
The clinical measurement of the concentration and activities of two prostate 
derived glycoproteins, prostate specific antigen (PSA) and prostatic acid phosphatase 
(PAP), in serum has been assessed for decades in attempts to detect prostate cancers. 
Concentrations of PSA in serum above 10 ng/ml reliably indicate the presence of cancers, 
yet PSA testing is limited in its ability to differentiate prostate cancer from benign 
prostate hyperplasia (BPH), and specificity of the test diminishes significantly at lower 
PSA values below 10 ng/ml37"39. Digital rectal exams (DRE) and determination of serum 
prostatic acid phosphatase (PAP) were the principal method for prostate cancer detection 
and staging before the advent of PSA testing, and they too have many limitations185'186. 
Serum PAP levels can still be used as an indicator of metastatic disease and possibly 
recurrence prediction48'49, but it has proven to have low specificities and sensitivities as a 
detection biomarker as compared to PSA33. While X-ray crystal structures have been 
reported for both human PSA and PAP124'187, there was little resolution of the glycan 
constituents of these proteins. Because of the known associations of changes in 
glycosylation associated with cancer progression83"86, characterization of the glycan 
constituents of PSA and PAP derived from clinical samples representing healthy and 
Reproduced with permission from Journal ofProteome Research 8 (2): 620-623, 2009. 
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different prostatic disease states could identify knew biomarker candidates for prostate 
cancer detection. 
PSA contains 8% carbohydrate by mass119, and has one glycosylation site at 
asparagine (Asn)-45120. Previous studies on PSA glycosylation have compared seminal 
plasma from healthy donors to prostate tumor metastatic cell line LNCaP115"117. PSA 
purified from the seminal fluid of healthy subjects have been characterized as having 
sialylated complex biantennary glycans, frequent core fucose modifications, high 
mannose glycans, and some terminal N-acetylgalactosamines117'121. PSA glycans isolated 
from LNCaP cell lines have also been characterized as having some triantennary 
structures116, as well as decreased sialic acid content and the presence of increased fucose 
and GalNAc content115. A recent comparison of the sialic acid content of free PSA and 
proPSA isolated from serum, seminal plasma and tissues from non-cancer control 
subjects and prostate cancer subjects was reported . Essentially no differences in 
sialylation content for the different forms of PSA were detected for any condition or 
sample122. A separate study of serum PSA derived glycans compared structural 
differences between free and complexed PSA123. Both forms of PSA were found to have 
mostly sialylated and fucosylated biantennary structures, while a few multiantennary 
complex structures were also identified . These previous studies did not evaluate the 
specific structural configurations for each oligosaccharide isolated, and very few numbers 
of clinical samples were used. PAP has three glycosylation sites at Asn-62, Asn-188, and 
Asn-301124,125, making it a more difficult target for site specific structural 
characterization, yet one that may be a suitable complement to PSA. An X-ray crystal 
structure of PAP from normal seminal plasma had reported that Asn-301 had glycan 
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modifications consisting of primarily high mannose oligosaccharides, while glycans at 
Asn-188 were less resolved, but consistent with complex structures containing sialic acid 
and fucose124. In relation to prostate cancer, a previous serial lectin analysis of PAP 
isolated from tissue in BPH and cancer subjects reported a decrease in high-mannose and 
hybrid glycans with core fucoses in cancer relative to BPH, and an increase of non-
fucosylated hybrids in PCa as compared to BPH125. 
The objective of our study described herein was to obtain purified forms of both 
PSA and PAP from a clinical cohort of seminal plasma from healthy, BPH and prostate 
cancer subjects for further glycan structural analyses. We hypothesized that 
characterization of these PSA and PAP glycoforms across specified clinical sample sets 
would identify a subset of glycan constituents as biomarker candidates for the detection 
of prostate cancers. Following a purification step using thiophilic chromatography, the 
released glycans from PSA and PAP were characterized using HPLC separation of 
aminobenozate derivatives, permethylation and MALDI-TOF/TOF profiling, and 
glycopeptide analysis on a hybrid triple quadrupole/linear ion trap mass spectrometer. 
The cumulative structures obtained for both PSA and PAP are reported and potential 
disease specific classes of glycoforms are identified. Specific assignments of glycan 
structural subtypes have also been determined for each of the three glycosylation sites on 
PAP. The glycan structures reported for PAP represent the first description of its glycan 
constituents using mass spectrometry based methods. 
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4.2 Experimental 
Seminal plasma samples 
Seminal fluid was obtained from men seen at the EVMS Department of 
Urology/Divine Tidewater Urology clinic for prostate cancer screening from 1989-2003. 
A semen collection kit was provided for each donor. Following semen collection, an 
instant freeze pack was applied to each tube for storage, and brought with the donor to 
the urology clinic. Following transport to the Virginia Prostate Center biorepository at 
EVMS, each sample was thawed, centrifuged to remove sperm, and stored in 0.5 ml 
aliquots. Initially, Normal (n=65), BPH (n=59), and PCa (n=92) pools (8-10 mis 
total/pool) were compiled from samples previously aliquoted for expression profiling 
studies (0.05 to 0.2 ml per sample), and matched for age. Each aliquot went through less 
than 2 freeze/thaw cycles, and average serum PSA values were 10.4 ng/ml (range 0.01 -
225.8 ) for PCa, 3.6 ng/ml (range 0.15 - 13.9) for BPH, and 1.5 ng/ml (range 0.3 - 4.8) for 
normal. The pooled samples were then subjected to a low-speed spin (4°C, 12k RPM, 20 
minutes) to remove any cellular contaminants, followed by ultracentrifugation (4°C, 37K 
RPM, 1 hour) to pellet out the prostasomes (membrane-bound storage vesicles secreted 
by prostate epithelial cells188). The supernatant was collected and 400ul aliquots were 
stored at -80° C. A more defined subset of seminal plasma pools were created for each 
clinical group, with each cohort having defined serum PSA values in the 2-7 ng/ml range. 
Nine samples, 500ul per sample, were used to make each seminal plasma pool, and the 
samples used were collected between 1997 and 2003. The mean serum PSA values were 
3.58 ng/ml for normal, 2.64 ng/ml for BPH, and 5.83 ng/ml for prostate cancer. BPH 
cases were defined as being biopsy negative, and the cancer samples were predominantly 
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Gleason grade 6 (3+3). These pools were processed as previously mentioned. The final 
supernatant of approximately 4.5 ml was aliquoted and stored at -80°C until needed. 
Protein concentrations were determined for all seminal plasma pools. 
Thiophilic adsorption chromatography (TAC) 
PSA and PAP were purified from seminal plasma pools using thiophilic 
adsorption chromatography (TAC) following the methods outlined by Kawiniski et al.189. 
Thiophilic adsorption chromatography uses a resin that consists of sulfone and thioether 
groups bound to agarose beads, which in turn binds proteins primarily via tryptophan and 
phenylalanine residues189"191. Briefly, seminal plasma pools were applied to Fractogel® 
EMD TA "T-gel" (Merck KGaG, Darmstadt, Germany) columns (2 cm x 0.5 cm) 
equilibrated in 1M sodium sulfate, and eluted in decreasing salt fractions. Protein content 
of each pool was normalized to 3.0 mg, with the samples in a final volume of 1ml in 
25mM HEPES/1M sodium sulfate. Next, the sample was applied to the column, 
followed by 2ml of column buffer, and allowed to flow through by gravity; this three 
milliliter fraction collected is named "unbound". The column was washed with 8 bed 
volumes of column buffer. Batch elution with decreasing sodium sulfate molarities 
(0.8M, 0.6M, 0.4M, 0.2M, and 0.0M) was performed using a low-pressure peristaltic 
pump. For each concentration, approximately 3ml fractions were collected, aliquoted, and 
stored at -80°C. The presence of PSA and PAP were confirmed by Western blot, and 
MALDI peptide mass fingerprinting of the corresponding excised gel bands was done to 
assess relative purity. MASCOT scores of greater than 100 and sequence coverage of 
greater than 45% were routinely observed for both PAP and PSA bands. 
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Normal Phase HPLC 
Rapid glycan sequencing of both PSA and PAP was performed by using 
previously optimized procedures192. Briefly, PSA and PAP gel slices were digested with 
PNGase F, then the released free glycans were labeled with 2-aminobenzamide (2-AB) 
for subsequent normal phase HPLC analysis193. A subset of samples were treated with 
Arthrobacter ureafaciens sialidase as previously described by Guile et al.194. The 
resulting peaks, separated by time of appearance, correspond to specific glycan structures 
on the basis of glucose unit values (data not shown)194. All HPLC analyses were 
performed using a Waters Alliance HPLC System and quantified using the Millennium 
Chromatography Manager (Waters Corporation, Milford, MA). 
N-glycan permethylation 
TAC-purified PSA and PAP gel bands derived from seminal plasma pools were 
permethylated195 following trypsin digestion. Gel bands were first reduced and alkylated, 
and then dried in vacuo prior to proteolytic digestion. Trypsin digestions were performed 
at 37°C for 18 hours, followed by peptide extraction with 50% acetonitrile/0.1% TFA and 
dried in vacuo. Next, trypsin was denatured by heating the sample at 100°C for 5 
minutes, and 1500 units of PNGase F (New England Biolabs, Ipswich, MA) was added to 
the peptide mixture and incubated at 37°C for 18 hours. The final digested product was 
purified using Resprep™ CI8 cartridges (Restek Corporation, Bellefonte, PA). The N-
glycan fraction was collected in 5% acetic acid, and subsequently dried under reduced 
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pressure. Dried N-glycans were permethylated following the protocol described by 
Ciucanu and Kerek195. The permethylated N-glycans were purified using CI8 columns, 
eluted in 85% acetonitrile, and then dried under a nitrogen stream. 
MALDI-TOF/TOF 
The dried permethylated N-glycans were reconstituted in 20 microliters of 100% 
methanol. Sample was mixed 1:1 with 2,5-Dihydroxybenzoic acid (DHB) matrix 
(20mg/ml in 50% methanol) and spotted on a polished steel MALDI-TOF target plate 
and allowed to crystallize at room temperature in the dark. Each sample was analyzed in 
positive ion mode using an UltraFlex III MALDI-TOF/TOF instrument (Bruker 
Daltonics, Germany). FlexControl and FlexAnalysis software (Bruker Daltonics, 
Germany) were used for spectra processing. Additionally, the glycan database offered by 
the Consortium for Functional Glycomics (http://www.functionalglycomics.org) was 
used to search permethylated glycan masses correlating to peaks of interest in MALDI-
TOF spectra. Glycan "cartoons" representing mass peaks were built using GlycanBuilder 
ver 1.2 build 3353196. 
Hybrid triple quadrupole/linear ion trap mass spectrometry 
A hybrid triple quadrupole/linear ion trap mass spectrometer 4000 (QTRAP® 
LC/MS/MS system, Applied Biosystems, Foster City, CA) coupled to a Tempo NanoLC 
system (Eksigent Technologies, Dublin, CA) was used to determine the structures of the 
glycans attached to each of the three PAP linkage sites: Asn-62, Asn-188, and Asn-301. 
The methods described by Sandra et al.197 were used with minor modifications to 
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optimize for our samples and instrumentation. Briefly, TAC-purified PAP gel slices 
derived from seminal plasma were reduced, alkylated, and digested with a saturated 
solution (in 50mM ammonium bicarbonate) of either 750 ng of trypsin or 950 ng of 
chymotrypsin. After an overnight digestion, the resultant peptides were extracted from 
the gel slice using 50% acetonitrile/0.1% TFA in water and dried in vacuo. The digested 
product was reconstituted in 20 microliters of Buffer A (5% acetonitrile/0.1% formic 
acid/0.005% heptafluorobutyric acid in water) and 8 microliters was injected into the 
nanoLC system for fractionation and analysis. Both the linear ion trap and the triple 
quadrupole capabilities of the QTRAP were utilized in these analyses. Glycopeptides 
were identified in the digestion mixtures by monitoring for unique marker oxonium ions 
such as m/z 163 (Hex*), 204 (HexNAc+), 292/274/256 (NeuAc+1), and 366 
(HexHexNAc+) that originate from fragmented glycopeptides197'198. In this approach the 
peptides are scanned in quadrupole 1 (Ql) to determine their masses and retention times. 
The peptides are then transmitted to quadrupole 2 (Q2) which acts as a collision cell 
where fragmentation occurs. Quadrupole 3 (Q3) is set to transmit only the mass of the 
diagnostic oxonium ions. Upon their detection, an enhanced product ion scan (EPI) of 
the precursor ion is triggered where fragmentation occurs in Q2, the fragmented ions are 
captured in the ion trap and then scanned out generating an MS/MS spectrum containing 
the ions from the both the peptide and the linked carbohydrate structures. 
4.3 Results 
Purification of PSA and PAP from seminal plasma pools 
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A large repository of seminal plasma fluids collected over the last 18 years were 
used to create pooled sample cohorts representative of normal control, benign prostatic 
hyperplasia (BPH) and prostate cancer conditions. A thiophilic adsorption 
chromatography (TAC) approach adapted from Kawiniski et al.189 was used to purify 
PSA and PAP from the prostasome depleted, pooled seminal plasma fluids. Following 
sequential batch elution, the resulting protein fractions were separated by SDS-PAGE, as 
shown in Figure 5. Under the conditions used, PAP did not bind to the TAC resin, and 
PSA eluted in both the 0.6M and 0.4M sodium sulfate fractions. Both PSA and PAP were 
readily detected by Coomassie staining, and their identities were confirmed in their 
respective fractions by western blotting and peptide mass fingerprinting. For both PSA 
and PAP isolated from gel slices, MASCOT scores of over 100 and sequence coverage of 
at least 45% were obtained. Lastly, there was no indication of other protein sequences 
present with significant scores. 
Rapid glycan sequencing analysis of PAP and PSA glycans 
The TAC fractions containing PSA and PAP were used for preparative SDS-PAGE 
separations, stained with Coomassie blue, and gel slices corresponding to PSA or PAP 
excised. Each gel band was digested with trypsin, followed by PNGaseF digestion and 2-
aminobenzamide derivatization of the released glycans as previously described193. 
Glycans from PSA and PAP for each of the three clinical groups were then separated by 
normal phase HPLC and their elution positions used to define structural classes194. The 
elution profile of PAP derived 2AB modified glycans from each pool is shown in Figure 
6. It is clear that there are major differences in glycosylation patterns detected for PAP, 
M 1 2 
PAP 
3 4 5 6 
4 * 
PSA 
Figure 5. Seminal plasma fractionation by thiophilic adsorption chromatography. 
Seminal plasma protein fractions purified by thiophilic adsorption chromatography 
(TAC) were separated on a 12% Bis-Tris NuPAGE SDS-gel (Invitrogen) and stained 
with Coomassie blue. Unbound proteins are shown in Lane 1, with protein from the 0.8M 
NaS04 elution in Lane 2, 0.6M (Lane 3), 0.4M (Lane 4), 0.2M (Lane 5) and 0 M/25mM 
HEPES (Lane 6). This gel shows the proteins from normal seminal plasma, and is 
representative of the purifications of the benign and cancer samples. PAP and PSA 
identities were confirmed in the above fractions by staining, western blots and MALDI-
TOF analysis. 
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Figure 6. Normal phase HPLC separation of 2-AB derivatized N-linked glycans 
from PAP. The relative levels of N-linked glycans from PAP isolated from normal 
control, benign (BPH) and prostate cancer (PCa) conditions separated by normal phase 
HPLC. Structural designation are as follows: A1G1, hybrid glycan with a single galactose 
residue on the 1,6 arm; FcA2, core fucosylated (1,6) agalactosylated biantennary glycan; 
Man6, High mannose glycan with 6 mannose residues, A2G2, biantennary N-glycan; 
Man7, High mannose glycan with 7 mannose residues; A3G3, triantennary N-linked 
glycan; FcA3G3, core fucosylated (1,6) triantennary N-linked glycan; A4G3, 
tetraantennary N-linked glycan with 3 galactose residues; A4G4, tetraantennary N-linked 
glycan; FcA4G4, core fucosylated (1,6) tetraantennary N-linked glycan. B indicates 
bisecting GlcNAc residues. 
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particularly in the comparison of healthy and benign relative to the cancer samples. 
Because of the known instabilities of terminal sialic acid residues during processing and 
HPLC analysis26, digestion with Arthrobacter ureafaciens sialidase was also done prior 
to normal phase HPLC separation to compare the non-sialylated structures. As 
summarized in Figure 7, there were still significant decreases in the fucosylated bi- and 
tetraantennary classes, FcA2G2 and FcA4G4, in the cancer samples. Either with or 
without sialidase treatment, there was also an apparent decrease in high mannose (Man6) 
structures in the cancer samples, and dramatic increases in cancer for truncated A1G1 
structures. A similar analysis for 2-AB labeled PSA glycans was done, as summarized in 
Figure 8 (no sialidase) and Figure 9 (with sialidase). Cumulatively, the types of glycan 
structures detected in these HPLC separations are consistent with previously reported 
structures for PSA115"117. There were no dramatic differences in expression of sub-types 
across the three clinical conditions, with the exception of the A2G2 structures in BPH in 
the non-sialidase treated preparation. Because this difference was not detected in the 
sialidase treated samples, this could reflect differential stabilities or sample processing 
differences. This will need to be further investigated in follow up studies. 
The seminal plasma pools used for these initial analyses represent a broad range 
of clinical samples reflecting the disease severity spectrum of prostate cancers and benign 
conditions collected from 1990 to 2003, a time frame that spans the pre-PSA testing era 
to current clinical practice. Using the PSA levels for each individual in the pool of these 
samples, a refined pooled subset of 9 samples per condition was generated based on dates 
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Figure 7. Normal phase HPLC separation of 2-AB derivatized N-linked glycans 
from PAP treated with sialidase. N-linked glycans from PAP isolated from normal 
control, benign (BPH), and prostate cancer (PCa) were treated with sialidase prior to 
normal phase HPLC separation. Shown are the relative intensities of each indicated 
structure per condition, normal (Gray bars); BPH (Black bars); PCa (White bars). 
Structural abbreviations are described in the legend for Figure 6. 
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PSA Glycans (no sialidase) 
Figure 8. Normal phase HPLC separation of 2-AB derivatized N-linked glycans 
from PSA. N-linked glycans from PSA isolated from normal control, benign (BPH) and 
prostate cancer (PCa) were separated by normal phase HPLC. Shown are the relative 
intensities of each indicated structure per condition, normal (Gray bars); BPH (Black 
bars); PCa (White bars). Structural abbreviations are described in the legend for Figure 6. 
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Figure 9. Normal phase HPLC separation of 2-AB derivatized N-linked glycans 
from PSA treated with sialidase. 
N-linked glycans from PSA isolated from normal control, benign (BPH), and prostate 
cancer (PCa) were treated with sialidase prior to normal phase HPLC separation. Shown 
are the relative intensities of each indicated structure per condition, normal (Gray bars); 
BPH (Black bars); PCa (White bars). Structural abbreviations are described in the legend 
for Figure 6. 
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reflects the majority of benign and prostate cancer subjects detected in the PSA 
screening/testing era, and hence results from these samples should be more reflective of 
current urological practice. The same sample preparation and TAC purification was done 
for each new pool. PAP and PSA eluted in their respective fractions as described in 
Figure 5 (Figure 10). As shown in Figure 11 for PAP, similar results to the larger pool 
data were obtained. There continued to be a larger proportion of fragmented glycans 
(A1G1, FcA2, A2G1, FcA2) in the prostate cancer samples relative to the healthy and 
BPH cohorts. PSA and PAP purified from this new cohort was used for all subsequent 
analyses. 
MALDI-TOF analysis of permethylated PSA and PAP glycans 
In order to further define the structural repertoire of PSA and PAP glycans, 
permethylation195 of the PNGase F released glycans was done for each clinical cohort, 
followed by MALDI-TOF/TOF analysis. Because of the broad diversity of the indicated 
structural classes from the HPLC analyses, the goal was not to identify disease specific 
changes, but to better define all of the possible glycan structures detected on seminal 
plasma PSA and PAP. Permethylation of glycans aids in the stability of the terminal 
sialylated residues for detection by MALDI-TOF/TOF, and simplifies the spectra to 
primarily Na+ adducts, allowing for less complex annotation of mass peaks. From the 
permethylation experiments, we were able to detect multiple glycoforms for both PAP 
and PSA (Table 2 and Table 3). A representative MALDI-TOF spectra of PAP derived 
permethylated glycans from prostate cancer samples are shown in Figure 12. 
Cumulatively, 21 structural classes of PAP glycans were detected representing primarily 
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Figure 10. Thiophilic adsorption chromatography of redefined seminal plasma 
pools. Seminal plasma protein fractions from normal, BPH, and PCa defined pools 
purified by thiophilic adsorption chromatography (TAC) were separated on a 12% Bis-
Tris NuPAGE SDS-gel (Invitrogen) and silver stained. Proteins that did not bind the 
TAC resin are shown in the lane marked Unbound, with protein from the 0.8M NaS04 
elution in Lane 1, 0.6M (Lane 2), 0.4M (Lane 3), 0.2M (Lane 4) and 0 M/25mM HEPES 
(Lane 5). PAP and PSA identities were confirmed in the above fractions by staining, 
western blots and MALDI-TOF analysis. 
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Figure 11. Normal phase HPLC separation of 2-AB derivatized N-linked glycans 
from PAP from the refined second sample pool. 
N-linked glycans from PAP isolated from the second pool of normal control, benign 
(BPH) and prostate cancer (PCa) seminal fluids stratified to PSA levels and other clinical 
parameters. Shown are the relative intensities of each indicated structure per condition 
following normal phase HPLC separation: normal (Gray bars); BPH (Black bars); PCa 
(White bars). Structural abbreviations are described in the legend for Figure 6. 
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Permethylated PAP glycans from normal, BPH, and PCa seminal plasma pools were 
analyzed by MALDI-TOF. Identified m/z values were used for database searches, and 
corresponding masses that could be assigned to a biologically relevant N-glycan structure 
are listed. An asterisk denotes structures that are one representation of multiple possible 
glycoforms for a given mass. The shown structure in these cases was chosen based on its 
apparent prevalence in mammalian species. Cartoon representations are as follows: • 
=GlcNAc, • =Mannose, O =Galactose, A=Fucose, ^=NeuAc, D=GalNAc 
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Permethylated PSA glycans from normal, BPH, and PCa seminal plasma pools were 
analyzed by MALDI-TOF. Identified m/z values were used for database searches, and 
corresponding masses that could be assigned to a biologically relevant N-glycan structure 
are listed. An asterisk denotes structures that are one representation of multiple possible 
glycoforms for a given mass. The shown structure in these cases was chosen based on its 
apparent prevalence in mammalian species. Cartoon representations are as follows: • 
=GlcNAc, • =Mannose, O =Galactose, A=Fucose, ^=NeuAc, D=GalNAc 
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Figure 12. MALDI-TOF analysis of permethylated PAP glycans from prostate 
cancer seminal plasma. A representative MALDI spectrum for permethylated PAP is 
shown. Combined with the structures determined in the control and BPH permethylated 
PAP samples, glycan structures corresponding to detected m/z peaks are listed in Table 2. 
63 
high-mannose and complex sub-types, with a few potential hybrid sub-types represented 
as well (Table 2). Permethylated glycans cleaved from PSA seemed to be mostly bi- and 
tri-antennary structures of the complex sub-type, but represented 40 potential classes, 
including high mannose and hybrid sub-types detected as well (Table 3). These results 
are consistent with structures previously reported for PSA glycans from serum and 
seminal fluids115"117122. 
Triple-quadrupole mass spectrometry analysis of PAP glycopeptides 
Because PAP has three distinct glycan sites, and the previously reported crystal 
structure was only able to definitively assign one high-mannose containing site, 
individual glycopeptide analysis of the three sites was initiated. SDS-PAGE separated 
PAP was proteolytically digested with trypsin or chymotrypsin, and peptides fractionated 
by nanoLC system in-line with triple quadrupole mass spectrometer. The instrument was 
operated in the precursor ion (PI) scan mode for individual sugar molecules at specific 
m/z values of either 163 for Hexose+1(Hex), 204 for N-acetylhexoseamine+1 (HexNAc), 
292/274/256 for N-acetylneuraminic acid+1 (NeuAc), or 366 for Hex-HexNAc+1. An 
enhanced product ion scan is triggered upon detection of the specified diagnostic ion, 
generating information on the sugar composition and the amino acid sequence of the 
glycopeptides in a single assay. An example is shown in Figure 13 for the tryptic peptide 
with one missed cleavage encompassing the high mannose site at Asn 301 
(GEYFVEMYYRNETQHEPYPLMLPGCSPSCPLER), as determined by the precursor 
ion scan for oxonium ion 163. Knowing the parent mass allows for annotation of the 
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Figure 13. Precursor ion scan for 163 m/z hexose of tryptic PAP peptides. 
A) Enhanced Product Ion (EPI) scan of a quadrupole-charged PAP glycopeptide with 
parent mass of 5449.0. 
B) Expanded window of above EPI scan showing fragmentation of the parent ion that 
corresponds to the tryptic peptide GEYFVEMYYRNETQHEPYPLMLPGCSPSCPLER 
containing the glycosylation site Asn-301 and a Man6 N-glycan. 
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constituents and fragments. The annotation of these glycans was greatly simplified as this 
site contains only high mannose structures, with Man6 being the major constituent, and 
Man7 a minor one, which is consistent with the PAP crystal structure124. Additionally, 
Figure 14 illustrates an example of the tryptic peptide with one missed cleavage 
encompassing the high mannose site at Asn 62 (FLNESYKHEQVYIR), as determined by 
the precursor ion scan for oxonium ion 292. As listed in Table 4, this approach has been 
useful for identifying complex biantennary and triantennary glycans at Asn 62. This site 
had previously been poorly resolved in the PAP crystal structure, such that complex 
glycan structures were proposed to be unlikely constituents9. Like in the crystal 
structure, the site at Asn 188 has proven elusive to glycan analysis, particularly when 
trypsin was used for digestion, which we believe was due to a combination of mixed 
tryptic cleavages combined with large tetra-antennary glycans. However, use of 
chymotrypsin allowed detection of an Asn 188 containing glycopeptides, consistent with 
attached tetraantennary glycan structures (Table 4). 
4.4 Discussion 
The need for improved prostate cancer biomarkers beyond the serum PSA test is 
increasingly evident. Because this test is applied to population screening, there is a 
wealth of data that indicates its strength in increasing detection of prostate cancers, but its 
use has also led to increased over-treatment and unnecessary surgeries for indolent 
disease. Despite its widespread use, there is still much characterization of PSA to be 
done, particularly in regards to its structural glycosylation properties and physiological 
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Figure 14. Precursor ion scan for 292 m/z hexose of tryptic PAP peptides. 
A) Enhanced Product Ion (EPI) scan of a quadrupole-charged PAP glycopeptide with 
parent mass of 3744.0. 
B) Expanded window of above EPI scan showing fragmentation of the parent ion that 
corresponds to the tryptic peptide FLNESYKHEQVYIR containing the glycosylation site 
Asn-62 and a complex biantennary, singly sialylated N-glycan. 
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Table 4. PAP glycopeptides with corresponding N-glycan structures identified by 
QTRAP 
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Both tryptic and chymotryptic PAP digests were analyzed by the QTRAP as described in 
the experimental section. PI scans for oxonium ions 163, 366, and 292 are represented in 
the above table. Certain EPI scans revealed glycopeptide information that allowed for the 
assignment of both peptide and glycan. 
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derived secreted glycoproteins like PSA have long been a source of this enzyme, 
particularly as it is generally present at concentrations that range from 100-400 ug/ml in 
this fluid. Using a large cohort of archived seminal plasma samples reflective of healthy, 
benign and prostate cancer conditions allowed systematic characterization of PSA for 
similarities and differences in its disease specific glycosylation patterns. While PSA 
glycosylation has been previously studied by many other groups ' , to our 
knowledge we are the first to examine PSA glycoforms across matched, disease-defined 
sample sets reflective of multiple samples. For a glycoprotein with one site of N-
glycosylation, the number of different glycan structures identified across the conditions 
analyzed is highly variable, ranging from predominant complex bi- or tetraantennary 
structures, to hybrid and high mannose glycoforms. In this regards, use of pooled 
samples to identify disease specific variants of PSA will be highly limiting. While it is 
appropriate to define the repertoire of potential structures, there were no conclusions that 
could be reached regarding specific disease glycoform variants of PSA. Methods that 
facilitate characterization of individual samples like targeted lectin-ELISA assays199 or 
specific selective reaction monitoring (SRM) approaches using instrumental 
configurations like the hybrid triple quadrupole MS assay for PAP will be necessary to 
better define disease specific glycoform changes for PSA. The diversity of glycan 
structures detected for PSA, and the well established role of PSA in clinical medicine and 
prostate disease, certainly warrant these types of approaches on larger sample cohorts. 
The cumulative glycan results for PAP represent the first characterization of PAP 
structures using mass spectrometry approaches. Previous reports indicated that PAP 
glycosylation at Asn-301 was of the high-mannose type, while it was hypothesized that 
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the Asn-188 site contained complex-type glycans and the Asn-62 site contained non-
complex structures124. Our results confirm that high-mannose glycoforms are present at 
the Asn-301 site, with the presence of Man6 and Man7 glycans observed for this site. 
Based on the data summarized in Table 4, we have found that sialylated complex-type 
glycans occupy the site at Asn-62, with bi- and tri-antennary structures present. The 
glycans attached to Asn-188 are less defined, but the preliminary results indicate a larger 
glycan constituent, most likely the tetra-antennary complex sialylated and fucosylated 
structures observed in the characterization studies (Table 3). Clearly, application of 
alternative proteases besides trypsin could better clarify the glycopeptide constituents of 
the Asn-188 site. Emerging improvements in computer programs like SimGlycan 
(Applied Biosystems/PremierBiosoft) that allow annotation of large complex glycan 
constituents will also facilitate this characterization. Conversely, the HPLC and MALDI-
TOF profiling indicated the presence of truncated glycan species predominantly in the 
prostate cancer samples. Their further characterization at the structural level, as well as 
their site of attachment, could lead to specific PAP glycan biomarker assays. 
Additionally, the described purification and analysis approaches for both PAP and PSA 
glycans are compatible with emerging quantitative isotope labeling strategies200. Missing 
for both PAP and PSA are any determinations of the anomeric linkages for the different 
glycan species, as linkage differences and positions of the sialic acid residues in 
particular could dictate biological and clinical differences. The permethylation strategies 
already utilized are equally valid for providing PSA and PAP glycans for more detailed 
MS/MS" structural characterization approaches201'202, and these are currently ongoing in 
our laboratories. 
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The cumulative glycan structural information from PSA and PAP is being used in 
a prostate cancer biomarker "pipeline" to develop specific lectin-ELISA assays199 
targeting fucosylation and sialylation differences, as well as targeted SRM and/or 
multiple reaction monitoring (MRM) assays in proximal prostatic fluids. These 
approaches are particularly advantageous for the analysis of many individual seminal 
plasma samples, as well as other proximal prostatic fluids termed expressed prostatic 
secretions (EPS) being collected for molecular genetic biomarker assays74' m . Expressed 
prostatic secretions are collected in voided urine following a standard urological digital 
rectal exam combined with prostate massage, and analysis of their glycoprotein 
constituents could complement and extend results reported in seminal plasma. In 
conclusion, there are multiple glycan targets of potential clinical relevance that warrant 
continued structural analysis of PAP and PSA glycopeptide species. The use of seminal 
plasma derived proteins will continue to facilitate this characterization, and can also be 
readily adapted to other clinical relevant proximal fluids of the prostate. 
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CHAPTER IV 
AIM II: ESTABLISH EXPRESSED PROSTATIC SECRETIONS AS A SOURCE 
OF PROSTATE-SPECIFIC ANTIGEN AND PROSTATIC ACID PHOSPHATASE 
5.1 Introduction 
Expressed prostatic secretions (EPS) are fluids derived directly from the prostate, 
which can be collected in different manners. EPS fluids have been routinely collected in 
the clinic since the late 1960's for the purpose of the diagnosis of chronic prostatitis and 
inflammatory chronic pelvic pain syndrome131203'204. Historically for the analysis of 
prostatitis, the prostate is forcefully massaged and the small amount of prostatic fluid is 
collected from the penis204, however this procedure can cause considerable pain for the 
patient. A second method involves squeezing the prostate ex vivo following a 
prostatectomy and collecting the fluid that drips from the gland205. A third method can 
be performed by the urological surgeon prior to surgery whereby the prostate is 
vigorously massaged while the patient is under anesthesia and prostatic fluid is pushed 
through the urethra and collected from the penis. It is this third method that is used to 
collect the direct EPS samples analyzed in this dissertation. A fourth method, and easiest 
to obtain clinically, is the collection of EPS in voided urine following a routine digital 
rectal exam (DRE) in the clinic. In this case, the prostate is gently massaged on both 
sides during the DRE exam, and is comparably less painful for the patient relative to the 
other collection methods. These fluids not only contain secreted proteins from within the 
prostatic infrastructure, but they also contain epithelial cells that are shed during the 
massaging process. EPS fluids are considered proximal fluids of the prostate and 
Figures 17 and 18 are adapted from Drake, RR et al., J of Proteomics. 2009 Aug 20;72(6):907-917. 
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therefore have potential as a rich source of biomarkers for prostatic diseases, especially 
cancer. In recent years, EPS fluids have been used for the development of genetic-based 
assays for prostate cancer detection have gained increased popularity74' 132-134>206-210 A 
subset of these assays focus on the cellular sediment obtained from EPS fluids for the use 
in prostate cell-associated PCA3 mRNA testing (APTIMA PCA3, Gen-Probe Inc, San 
Diego, CA), without analyzing the supernatant ' " . Another epithelial-based target 
from the EPS urine sediment is the TMPRSS2-ERG fusion transcript which has been 
shown to positively correlate with prostate cancer74'134'2U. 
EPS fluids have yet to gain popularity for the detection and discovery of current 
and new protein-based prostate cancer biomarkers. We hypothesize that EPS fluids are 
an enriched source of prostate derived proteins like PSA and PAP, and therefore can be 
useful for development of subsequent assays involving these two biomarkers. The 
objective of this aim is to determine how readily detectable PSA and PAP are in EPS 
fluids, and to determine if these fluids can be used in proteomic and glycomic based 
experiments. We found through fractionation, gel-separation, and mass spectrometry 
technologies that EPS fluids are indeed an enriched source of both PSA and PAP and 
have great potential for discovery, validation, and clinical collection for future early 
prostate carcinoma detection assays. 
5.2 Experimental 
Expressed prostatic secretions and urine samples 
Urine samples, EPS urine samples, and direct EPS samples were acquired from 
the Virginia Prostate Center (VPC) Biorepository, with EPS sample collection beginning 
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in January 2007. Individuals providing the EPS urines are men who are scheduled for a 
prostate biopsy at the clinic and have consented to having additional samples collected 
for research purposes. When patients also provide a non-EPS urine sample, the voided 
urine is collected one hour prior to the DRE. EPS urines are collected following the DRE 
(10-20 ml), and are stored on ice for less than one hour at the clinic prior to transport to 
the biorepository. Once at the biorepository the samples are centrifuged to remove the 
cellular sediment, aliquoted, and all fractions and aliquots are stored at -80°C. 
Two samples were collected from one individual on the same day. The first 
sample was collected prior to the DRE, and was noted as "pre-DRE urine." The second 
sample was collected following a routine DRE, and was termed "post-DRE urine" or 
"EPS urine." Approximately two milliliters were obtained of each sample, and protein 
concentrations were determined prior to any analysis. These samples were used for 20-
PAGE and LC-ESI-MS/MS analyses. 
A single direct EPS sample was collected from a patient prior to a radical 
prostatectomy. The collection of this sample involves a vigorous massage of the prostate 
gland while the patient is under anesthesia during the pre-surgery exam, resulting in the 
collection of pure prostatic secretions via the urethra (0.5-1 ml). The sample is then 
stabilized in a sterile saline solution prior to centrifugation to obtain the cellular 
sediments and subsequently aliquoted and stored at -80°C. 
In addition to individual sample analysis, pools of samples were generated, based on 
clinical diagnoses. An initial set of five pools were created based on the following 
disease risk stratification: normal, BPH, low PCa, intermediate PCa, and high PCa (Table 
1). Each pool comprised of six individual EPS urines; four milliliters per individual, for 
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a total volume of 24 milliliters. The individual samples were first subjected to a low-
speed centrifugation (RT, 5K RPM, five minutes) to remove any additional contaminants 
prior to pooling. The pools were concentrated using Amicon Ultra centrifugal filter 
devices with a 10 kDa cut-off (Millipore, Carrigtwohill, Co. Cork, Ireland) and low-speed 
centrifugation (4°C, 4.5K RPM, approximately 1 hour), resulting in a final volume of 
approximately two milliliters per pool. Protein concentrations were determined for each 
enriched pool. These pools were used for ID-PAGE, 2D-PAGE, western blotting, and 
2DE western blotting. 
A second set of EPS urine pools were created based on the following 
stratifications BPH, low PCa risk, high PCa risk, and metastatic PCa (Table 1). Four 
milliliters each of six samples were combined to create each EPS urine pool. These pools 
were generated following the same protocol as for the above set of pools, with a final 
volume of approximately two milliliters, and protein concentrations were also obtained. 
This subset of pools was used for TAC, ID-PAGE, and western blot analyses. 
Two-dimensional PAGE 
Two-dimensional PAGE was performed following the manufacturer's protocol (BioRad 
Laboratories Inc, Hercules, CA). Briefly, protein mixtures were combined with a 
rehydration buffer, applied to an IEF strip (11cm, pH 3-10), and passively rehydrated at 
room temperature overnight. The strips were then applied to the first dimension in a 
BioRad IEF focusing unit, followed by two equilibration steps and the second 
dimensional SDS-PAGE. For gels undergoing 2D-PAGE alone, the gels were either 
silver stained or Coomassie blue stained. For 2DE western blotting, the gels were then 
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transferred to PVDF membrane and processed following a standard western blotting 
protocol. Two hundred micrograms of each EPS urine pool (normal, BPH, low PCa, 
intermediate PCa, high PCa) was albumin and IgG depleted using commercially available 
spin columns (Sigma) following the manufacture's protocol and precipitated (10% TCA) 
prior to 2DE analysis and silver staining. Additionally, thirty micrograms per pool were 
combined together for a total protein concentration of 150 micrograms; in duplicate. 
These two pools were albumin and IgG depleted (ProteoPrep® Immunoaffinity albumin 
and IgG Depletion Kit, Sigma-Aldrich, St. Louis, MO) and 10% TCA precipitated prior 
to 2-DE analysis. One gel was silver stained while the mirror gel was transferred to 
PVDF for western blotting. 
Western blotting 
Western blotting for the detection of both PSA and PAP was performed following 
a standard western blot protocol. Briefly, gel-separated proteins were transferred to 
PVDF membrane using a semi-dry transfer element (BioRad Laboratories Inc, Hercules, 
CA). Blots were blocked with 5% milk in tris-buffered saline (TBS) for one hour 
followed by an overnight incubation in primary antibody. For PSA, a primary antibody 
was applied at a 1:3000 dilution in a 5% milk-TBS solution (goat anti-PSA affinity 
purified, Biodesign International, Saco, ME). For PAP, a primary antibody generated by 
our laboratory (mouse anti-PAP, protein A purified) was applied at a 1:1000 dilution in a 
5% milk-TBS solution. After removal of the primary antibody, blots were washed before 
addition of secondary antibodies (for PSA used 1:50,000 dilution of anti-goat IgG-HRP; 
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for PAP used 1:5000 dilution of donkey anti-mouse IgG-HRP, Santa Cruz 
Biotechnology). After one hour incubation with secondary antibody, the blots were 
washed and a chemiluminescent buffer system was added to the blot for protein detection 
(Immun-Star HRP, BioRad Laboratories Inc, Hercules, CA). 
Enzyme-linked immunosorbent assay (ELISA) 
An ELISA assay was performed following a protocol previously reported by 
Alexander et al212. Briefly, 50 microliters of EPS urines were diluted 1:1 in coating 
buffer (10 mM NaCl/50 mM NaP04, pH 7.5) and incubated overnight at 4°C in 96-well 
plates. The plate wells were next blocked with the same coating buffer and 0.5% bovine 
serum albumin, followed by an overnight incubation at 4°C with rabbit polyclonal 
primary antibodies for PSA (1:500 dilution) or PAP (1:1000 dilution) (Abeam Inc, 
Cambridge, MA). Finally, enzyme activity was detected using a secondary antibody 
conjugated peroxidase assay (BioRad Laboratories Inc, Hercules, CA). Commercially 
available purified standards from seminal fluids (Fitzgerald Industries, Concord, MA) 
were used to generate linear standard curves for both PSA and PAP. 
Thiophilic adsorption chromatography (TAC) 
Thiophilic adsorption chromatography (TAC) was performed as previously 
described in Chapter IV with minor modifications to optimize the protocol for this 
physiologically different fluid. Briefly, 0.75 milligrams of total protein per pool (BPH, 
low PCa risk, high PCa risk, metastatic PCa) was loaded onto each column with a total 
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volume of three milliliters (sample and column buffer). Approximately four milliliters 
was collected for each unbound fraction, and two milliliters for each subsequent fraction. 
LC-ESI-MS/MS 
Three individual samples ("pre-DRE urine", "post-DRE EPS urine", and "direct 
EPS") were trypsin digested and analyzed for protein content using an LTQ™ Linear Ion 
Trap (ThermoFinnigan, San Jose, CA). Ten micrograms of each sample was acetone 
precipitated and the pellets were reconstituted in ten microliters of 25 raM ammonium 
bicarbonate prior to digestion with paramagnetic immobilized trypsin beads 
(EnzyBeads™ Trypsine, Agro-Bio, La Ferte Saint Aubin, France) following a protocol 
developed by our laboratory. Briefly, samples were reduced by adding 100 mM of DTT 
to each sample and incubating them at 56°C for one hour. After samples cooled to room 
temperature, samples were alkylated in the dark for twenty minutes using 100 mM 
iodoacetamide. While samples alkylate, 25 ul of trypsin beads were washed three times 
with 25 mM ammonium bicarbonate. The wash buffer was removed from the beads, and 
ten microliters of sample was added to the beads and mixed thoroughly. The bead and 
sample mixture was incubated at 37°C for thirty minutes. The reaction was quenched by 
removing the sample from the beads (using a magnetic separator) and placing the sample 
in a new vessel. Two microliters of each sample was then used for LTQ analysis. 
Digests were resuspended in 20 jxl Buffer A (5% acetonitrile, 0.1% formic acid, 0.005% 
heptafluorobutyric acid) and 10 ul were loaded onto a 12-cm x 0.075 mm fused silica 
capillary column packed with 5 uM diameter C-18 beads (The Nest Group, 
Southborough, MA) using a N2 pressure vessel at 1100 psi. Peptides were eluted over 
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300 minutes, by applying a 0-80% linear gradient of Buffer B (95% Acetonitrile, 0.1% 
Formic Acid, 0.005% HFBA) at a flow rate of 150 ul/min with a pre-column flow splitter 
resulting in a final flow rate of-200 nl/min directly into the source. A LTQ™ Linear Ion 
Trap (ThermoFinnigan, San Jose, CA) was run in an automated collection mode with an 
instrument method composed of a single segment and 5 data-dependent scan events with 
a full MS scan followed by 4 MS/MS scans of the highest intensity ions. Normalized 
collision energy was set at 28%, activation Q was 0.250 with minimum full scan signal 
intensity at 1 x 105with no minimum MS2 intensity specified. Dynamic exclusion was 
turned on utilizing a three minute repeat count of 2 with the mass width set at 1.0 m/z. 
Protein searches were performed with MASCOT version 2.2.0 v (Matrix Sciences, 
London GB) using the SwissProt version 51.3 database. Parent ion mass tolerance was 
set at 1.5 and MS/MS tolerance 0.5 Da. 
5.3 Results 
2-D PAGE analysis of matched urine and EPS fluids 
A matched set of urine samples were collected from one patient in the clinic, with 
one sample being collected prior to the DRE exam and the other sample being collected 
following the DRE exam. Seven hundred microliters of each sample was acetone 
precipitated, the proteins were separated by 2D-PAGE and the gels were silver stained. 
These gels were compared to one another to look for differences in protein patterns 
among the two samples, specifically in the mass ranges where we expect to find PSA (32 
kDa) and PAP (50 kDa). There are clear differences in spot patterns all over the gel as 
well as in the mass ranges we expect to PSA and PAP (Figure 15). 
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Figure 15. Comparison of pre-DRE urine to post-DRE urine. A matched set of urine 
samples were collected from one patient in the clinic, with one sample being collected 
prior to the DRE exam (panel A) and the other sample being collected following the DRE 
exam (panel B). Each sample was acetone precipitated, the proteins were separated by 
2D-PAGE, and the gels were silver stained. 
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LC-ESI-MS/MS analysis of protein content of matched urine and EPS fluids 
Ten micrograms of precipitated protein from the above matched samples was 
trypsin digested and run on the LTQ instrument in order to analyze the total protein 
content. The samples were first reduced and alkylated before being proteolytically 
digested using trypsin bound to magnetic beads. The tryptic peptides were run against 
the standard peptide identification gradient and the resultant spectrum were searched by 
MASCOT for identification of proteins. For the pre-DRE urine sample, PSA and PAP 
are not on the list of 45 significantly identified proteins, whereas for the post-DRE EPS 
urine sample, 65 proteins were significantly identified, with PSA and PAP being in the 
top 10 significant hits (Table 5 and Table 6). For the single direct EPS sample analyzed, 
10 micrograms of protein was trypsin digested, and the digested peptides were also run 
on the LTQ instrument and analyzed for protein content. MASCOT searches identified 
74 significant proteins, with PSA and PAP being among the top 20 significant hits (Table 
7). 
TAC fractionation of EPS fluids and detection of PSA and PAP by western blot 
The subset of pools containing disease stratifications BPH, low PCa, high PCa, 
and metastatic PCa were TAC fractionated as described in the experimental section. A 
lOOul aliquot of each eluted fraction was 10% TCA precipitated in duplicate, the proteins 
were separated by ID-PAGE, and the gels were subsequently either silver stained or 
transferred to PVDF for western blot analysis. Figure 16 shows the resulting ID-PAGE 
gels for each disease condition. PAP was found to elute in the unbound fraction, 
therefore not binding to the TAC resin. PSA was found to elute across fractions 2, 3, and 
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Insulin-like growth factor-binding protein 7 
Ig alpha-1 chain C region 
Ribonuclease pancreatic 
Clusterin 
Ig lambda chain C regions 
Pro-epidermal growth factor 
Polymeric immunoglobulin receptor 
Actin, alpha skeletal muscle 
Actin, alpha cardiac muscle 
Actin, cytoplasmic 1 
ANKRD26-like family C member 1A 
ANKRD26-like family C member IB 
Inter-alpha-trypsin inhibitor heavy chain H4 
Ig gamma-2 chain C region 
Cubilin 
Alpha-2-HS-glycoprotein 
L-lactate dehydrogenase B chain 
Lysosomal alpha-glucosidase 
Attractin 
Urokinase-type plasminogen activator 
Mannan-binding lectin serine protease 2 
Golgi membrane protein 1 
Immunoglobulin J chain 
Vitamin D-binding protein 
Ubiquitin conjugation factor E4 B 
CD44 antigen 






















































































Sperm flagellar protein 2 
Beta-2-microglobulin 
Bone morphogenetic protein receptor type-IB 
Vitronectin 
GPN-loop GTPase 1 
Ciliary neurotrophic factor receptor alpha 
Mitochondrial GTPase 1 

















Two micrograms of reduced, alkylated and trypsin digested peptides were applied to an 
LTQ™ Linear Ion Trap (ThermoFinnigan) mass spectrometer in the data-dependent 
acquisition mode for mass spectrometry analysis. Survey full scan MS spectra (m/z 300 
to 1800) were acquired, with the four most intense ions in a scan sequentially isolated and 
fragmented in the linear ion trap by MS/MS. The peptide sequences were identified from 
their tandem mass spectra using Mascot in conjunction with the SwissProt database, and 
by using the following search criteria: carbamido-methylation of cysteine and oxidation 
of methionine residues as variable modifications, 1 missed enzyme cleavage site, and an 
error tolerance of 1.5 Da for MS and 0.5 Da for MS/MS. 
Table 5, Continued. 
83 










































Prostatic acid phosphatase 
Ig kappa chain C region 
Ig alpha-1 chain C region 
Prostate-specific antigen 
Alpha-2-HS-glycoprotein 
Polymeric immunoglobulin receptor 
Prothrombin 
Osteopontin 
Transmembrane protease, serine 2 




Brain acid soluble protein 1 
Ig gamma-1 chain C region 
Serotransferrin 
Amyloid beta A4 protein 
Ig gamma-2 chain C region 
Vasorin 
Carboxypeptidase E 







Vitamin D-binding protein 
Haptoglobin-related protein 
Leucine-rich repeat-containing protein 47 
Heat shock protein HSP 90-alpha 
Ribonuclease pancreatic 
Ig heavy chain V-III region GA 














































































































Receptor-type tyrosine-protein phosphatase eta 
Aminopeptidase N 
Ig heavy chain V-III region WEA 
Non-secretory ribonuclease 
Talin-1 
Ras-related protein R-Ras2 
L-xylulose reductase 
Peptidyl-prolyl cis-trans isomerase A 
Heat shock 70 kDa protein 1 
Tetraspanin-6 
Collagen alpha-1 (XV) chain 
14-3-3 protein theta 
Heat shock 70 kDa protein 6 
Heat shock 70 kDa protein 1L 
Heat shock cognate 71 kDa protein 





Ryanodine receptor 2 
Splicing factor 3B subunit 1 
Syndecan-4 

























































Two micrograms of reduced, alkylated and trypsin digested peptides were applied to an 
LTQ™ Linear Ion Trap (ThermoFinnigan) mass spectrometer in the data-dependent 
acquisition mode for mass spectrometry analysis. Survey full scan MS spectra (m/z 300 
to 1800) were acquired, with the four most intense ions in a scan sequentially isolated and 
fragmented in the linear ion trap by MS/MS. The peptide sequences were identified from 
their tandem mass spectra using Mascot in conjunction with the SwissProt database, and 
by using the following search criteria: carbarnido-methylation of cysteine and oxidation 
of methionine residues as variable modifications, 1 missed enzyme cleavage site, and an 
error tolerance of 1.5 Da for MS and 0.5 Da for MS/MS. 
Table 6, Continued. 






































Proteins significantly identified 
Protein-glutamine gamma-glutamyltransferase 4 
Serum albumin 
Brain acid soluble protein 1 
Lactotransferrin 
Ig kappa chain C region 
Aminopeptidase N 
Zinc-alpha-2-glycoprotein 
Creatine kinase B-type 
Actin, cytoplasmic 1 
Prostate-specific antigen 
Phosphatidylethanolamine-binding protein 1 
Neprilysin 
Prostatic acid phosphatase 
Myristoylated alanine-rich C-kinase substrate 
Ig alpha-1 chain C region 
Cytochrome b561 
Semenogelin-2 
Actin, aortic smooth muscle 
ANKRD26-like family C member 1A 
Transmembrane BAX inhibitor motif-containing protein 1 
Isocitrate dehydrogenase [NADP1 cytoplasmic 
Serotransferrin 
Ig kappa chain V-III region SIE 
Galectin-3-binding protein 
Heat shock protein HSP 90-beta 
Peptidyl-prolyl cis-trans isomerase A 
Putative zinc-alpha-2-glycoprotein-like 1 
Ig gamma-1 chain C region 
Ig lambda chain C regions 
Semenogelin-1 
Ig gamma-4 chain C region 
Macrophage migration inhibitory factor 
Kappa-actin 
Beta-actin-like protein 2 
Putative heat shock protein HSP 90-beta 4 




















































































































Ig gamma-2 chain C region 
Receptor-type tyrosine-protein phosphatase S 
Dipeptidyl peptidase 4 
IgGFc-binding protein 
Polymeric immunoglobulin receptor 
Annexin A5 
Ras-related protein Rab-4A 
Ras-related protein Rab-8B 
Ras-related protein Rab-39B 
Ras-related protein Rab-30 
Ras-related protein Rab-15 
Ras-related protein Rab-35 
Ras-related protein Rab-3B 
Ras-related protein Rab-6A 
Ras-related protein Rab-3C 
Ras-related protein Rab-37 
Ras-related protein Rab-3A 
Ras-related protein Rab-1 A 
Ras-related protein Rab-33B 
Calcineurin subunit B type 1 
Glycogen phosphorylase, brain form 
Ras-related protein Rab-27A 
Annexin A3 
Heat shock 70 kDa protein 1 
Prostasin 
Apoptosis-inducing factor 2 
Structural maintenance of chromosomes protein 5 
Protein S100-A8 
Zinc finger protein ZXDC 
Nephrocystin-3 
Fatty acid synthase 
Synaptotagmin-like protein 5 
RalBPl-associated Eps domain-containing protein 2 
BUD 13 homolog 
Myosin-Ixb 













































































Table 7, Continued. 
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Two micrograms of reduced, alkylated and trypsin digested peptides were applied to an 
LTQ™ Linear Ion Trap (ThermoFinnigan) mass spectrometer in the data-dependent 
acquisition mode for mass spectrometry analysis. Survey full scan MS spectra (m/z 300 
to 1800) were acquired, with the four most intense ions in a scan sequentially isolated and 
fragmented in the linear ion trap by MS/MS. The peptide sequences were identified from 
their tandem mass spectra using Mascot in conjunction with the SwissProt database, and 
by using the following search criteria: carbamido-methylation of cysteine and oxidation 
of methionine residues as variable modifications, 1 missed enzyme cleavage site, and an 
error tolerance of 1.5 Da for MS and 0.5 Da for MS/MS. 
Table 7, Continued. 
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Figure 16. 1D-PAGE analysis of TAC fractionated EPS urine samples. Thiophilic 
adsorption chromatography (TAC) was used to fractionate pooled EPS urine fluids. The 
collected fractions were then run on 12% Bis-Tris gels, and silver stained. The disease-
defined pools fractionated were BPH (Panel A), low risk PCa (Panel B), high risk PCa 
(Panel C), and metastatic PCa (Panel D). Lane 1 contains proteins that did not bind the 
TAC resin, with subsequent sodium sulfate elutions in Lane 2 (0.8M), Lane 3 (0.6M), 
Lane 4 (0.4M), Lane 5 (0.2M), and Lane 6 (O.OM). PSA and PAP were detected in 
respective fractions by gel staining and western blotting. 
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four which represent 0.6M, 0.4M, and 0.2M sodium sulfate elution fractions respectively, 
with the majority of PSA being detected in the 0.4M fraction (Figure 16). 
2-DE western blot analysis for PSA and PAP from EPS fluids 
A large pool of a subset of EPS urine pools (normal, BPH, low PCa risk, 
intermediate PCa risk, and high PCa risk) was created to examine the feasibility of 
detecting PSA and PAP in these fluids. In order to better examine the isoforms of both 
PSA and PAP, western blot analysis was performed on 2D-PAGE separated proteins. 
The total 150 ug of protein (in duplicate) was first albumin and IgG depleted using spin 
columns and then 10% TCA precipitated prior to 2D-PAGE analysis of mirror gels. One 
gel was silver stained for total protein content examination, while the second gel was 
transferred to PVDF membrane for western blotting. The blot was first probed and 
detected for PAP, then stripped of the primary and secondary antibodies as well as the 
ECL reagents (Restore western blot stripping buffer, Pierce-Thermo Fisher Scientific Inc, 
Rockford, IL), followed by probing for and detection of PSA. Figure 17 illustrates the 
2D-PAGE map of all proteins detected by silver staining from EPS urines, as well as the 
2D-PAGE pattern for both PSA and PAP isoforms and glycoforms in these EPS urine 
fluids213. 
ELISA analysis of PSA and PAP concentrations in EPS fluids 
ELISA assays were performed in order to examine the levels of PSA and PAP 
present in the EPS samples used in the aforementioned experiments. We found that for 
the majority of EPS urines there is a detection range of 10-40 ug/ml for PSA and 3-10 
ug/ml for PAP. Additionally, we observed a range of 80-120 ug/ml for PSA and 20-40 
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Figure 17. 2D-PAGE western blot analysis of PSA and PAP in EPS urine samples. 
Five disease-defined pools (normal, BPH, low risk PCA, intermediate risk PCa, high risk 
PCa) of EPS urines were combined together to make a general EPS urine pool unrelated 
to disease state and used for 2D-PAGE immunoblotting for the detection of both PSA and 
PAP. Two identical 8-16% Criterion Tris-HCl gels (BioRad) were run concurrently 
following the first dimension separation of EPS urine proteins. Following the gel 
electrophoresis, one gel was silver stained, while the second gel was transferred to PVDF 
membrane and western blot analysis was performed for both PSA and PAP. The silver 
stained gel and the PSA and PAP western blots are shown above with PAP and PSA 
spots highlighted on the silver stained gel. Adapted from Drake et al., 2009. 
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ug/ml for PAP in direct EPS fluids derived from cancer patients. Figure 18 illustrates the 
PSA and PAP levels across non-cancer (normal and BPH) and prostate cancer disease 
states (low risk, intermediate risk, high risk) in EPS urines. Lower levels of both PSA 
and PAP are observed in the prostate cancer EPS fluids as compared to the non-cancer 
samples. 
5.4 Discussion 
EPS fluids have routinely been collected in the clinic for the detection of 
prostatitis and chronic pelvic inflammatory disease, and the epithelial cell pellets 
resulting from these fluids are being used in a number of genetic-based assays for 
prostate cancer detection74'132"134,206-210 Proteomic profiling of other bodily fluids such 
as seminal fluid and urine have been conducted ' , however with no published studies 
to date, other than ours213, involving protein analysis of the EPS fluids, our current 
analyses are novel and therefore are capable of providing the field with a wealth of new 
knowledge. With our present studies, we have determined that post-DRE "EPS" urines 
are an enriched source of prostate-derived proteins (Table 6), with PSA and PAP being 
the most important targets for this dissertation. 
We have observed a clear difference in protein content between urine and EPS 
urines collected from the same patient within the same day, with a detectable presence of 
prostate-related proteins in the post-DRE urines as compared to the pre-DRE urines. This 
has been demonstrated by both 2D-PAGE analysis and LC-ESI mass spectrometry 







































Figure 18. Concentration of PSA and PAP in EPS urines. ELISA assays were used 
to assess the concentrations of PSA (A) and PAP (B) in non-cancer (normal and BPH) 
and cancer (low risk, intermediate risk, and high risk) EPS urines, with the results 
displayed in the above box plots. The EPS urines were combined 1:1 with coating buffer 
(10 mM NaCl/50 mM NaP04, pH 7.5), and incubated overnight at 4°C in 96-well plates. 
On the next day, the wells were blocked with 0.5% bovine serum albumin in coating 
buffer; followed by an overnight incubation with primary antibody at 4°C. Finally, 
secondary antibodies conjugated to peroxidase allowed for detection of the enzyme 
activity on the next day. The above diagram plots the mean, 10th, 25th, 75th and 90th 
percentiles as vertical boxes with error bars, with outlier samples shown as dots outside 
of the box. Adapted from Drake et al., 2009. 
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Table 6). These analyses indicate a relative increase in protein abundance in the post-
DRE urine as compared to the pre-DRE urine based on the spot patterns observed in the 
2D- PAGE gels and the increase in numbers of proteins identified by mass spectrometry. 
In addition, we have found that both PSA and PAP are among the top most significant 
proteins identified in both EPS urine and direct EPS fluids (Table 5, Table 6, and Table 
7) based on the LC-ESI mass spectrometry analysis. Additionally, we have successfully 
fractionated EPS urines by thiophilic adsorption chromatography, and have identified 
both PSA and PAP in their respective fractions (Figure 16). This fractionation scheme 
provides us with partially purified forms of PSA and PAP which can be further gel-
purified and used in subsequent mass spectrometry-based assays for both protein and 
carbohydrate analyses. In addition, we have also effectively used 2D-PAGE western blot 
analysis to detect individual isoforms of both PSA and PAP derived from EPS urines 
(Figure 17). These isoforms likely indicate various glycoforms of PSA and PAP, 
therefore providing us with the ability to use these fluids to identify and target individual 
glycoforms for both proteins, which may be indicative of various prostate disease states, 
such as BPH and cancer. Finally, we used ELISA assays to examine the concentration of 
PSA and PAP in EPS fluids (Figure 18). We observed that there are decreased levels of 
both PSA and PAP in the cancer samples as compared to the non-cancer samples, which 
correlate with increased PSA and PAP levels seen in blood of some cancer patients. For 
the EPS urine samples used the non-cancer group had an average serum PSA level of 4.6 
ng/ml (+/- 2.0; range 0.7- 7.9), and the cancer group had an average serum PSA level of 
6.8 ng/ml (+/-5.0; range 0.1-24.5). It is likely that we are seeing lower protein levels 
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derived from the prostate as these proteins are leaked into the blood stream in some 
prostate cancer states. 
All of these abovementioned characteristics will allow us to use these types of 
prostatic fluids in more targeted glycoproteomic and glycomic studies, with the intention 
of discovering superior biomarkers for the early diagnosis of prostate carcinomas. While 
direct EPS fluids are a great discovery fluid, they are not readily obtained in the clinic 
during a routine physical exam, as these fluids are collected under anesthesia prior to 
radical prostatectomy. However, EPS urines are useful as a discovery tool and are easily 
collected in the clinic during a routine physical exam, therefore making EPS urine fluids 
relevant for validation and use in clinical assays for the detection of early prostate 
carcinomas in the near future. 
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CHAPTER V 
AIM III: APPLICATION OF NEW METHODOLOGIES TO EXPRESSED 
PROSTATIC SECRETIONS FOR PROSTATE CANCER GLYCOPROTEIN 
BIOMARKER DISCOVERY 
6.1 Introduction 
As previously stated, EPS fluids are proximal to the prostate and therefore are an 
enriched source of potential biomarkers for the detection of early prostate cancer. We 
have also demonstrated in aim II the enriched presence of prostate-derived proteins in 
post-DRE urines as compared to pre-DRE urines (Table 5 and Table 6). While genetic-
based tests are already on the market74' 132-134>206-2105 the use of EPS fluids for proteomic 
analyses and assays is not widely observed. In addition to potential protein biomarkers, 
the carbohydrate structures attached to glycoproteins may also provide the diagnostic 
information needed for better disease biomarkers. We hypothesize that by performing 
initial glycomic and glycoproteomic studies using EPS samples we will build the 
foundation for more targeted biomarker studies with the focus on the carbohydrate 
structures attached to secreted glycoproteins. As PSA and PAP are two prominent 
prostate-derived proteins, they make ideal targets for glycoproteomic and glycomic 
studies. 
In addition to these two specific targets, total glycan approaches also have great 
utility in glycomic studies. First, the total glycan profile for a given fluid across differing 
disease states, such as cancer versus non-cancer, may provide a panel of altered 
glycoforms that can be used diagnostically for the detection of a given disease state, such 
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as prostate cancer. Secondly, once candidate glycoforms are identified, it may be 
possible to determine which proteins these glycoforms are attached to, allowing for the 
subsequent generation of protein-based biomarker clinical assays. The objective of this 
aim is to examine the glycosylation state of both PSA and PAP in EPS urine samples, as 
well as to examine the total glycan constituents in EPS urine and direct EPS samples. 
These goals will be achieved by first obtaining cleaved glycans from PSA and PAP 
derived from EPS urine samples, permethylating the free structures, and analyzing them 
by MALDI-TOF mass spectrometry. Next, we will use EPS urine-derived PAP in 
glycopeptide analyses using a triple quadruple mass spectrometer in precursor ion 
scanning mode with the intent to identify individual glycoforms at each N-linked 
glycosylation site of PAP. And finally, we will obtain a fraction of cleaved glycans from 
EPS urine and direct EPS pools, permethylate these structures and analyze them by 
MALDI-TOF/TOF. We have determined that EPS urine-derived PAP glycans have a 
great potential in providing glycomic targets for better clinical assays. Additionally, total 
glycan profiles of EPS urine and direct EPS fluids may also provide valuable diagnostic 
glycan-based biomarkers for the detection of early prostate carcinomas. 
6.2 Experimental 
Expressed prostatic secretion samples 
EPS urine and direct EPS samples were acquired from the Virginia Prostate 
Center (VPC) Biorepository, with EPS sample collection beginning in January 2007. 
Individuals providing the EPS urines are men who are scheduled for a prostate biopsy at 
the clinic and have consented to having additional samples collected for research 
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purposes. When patients also provide a non-EPS urine sample, the voided urine is 
collected one hour prior to the DRE. EPS urines are collected following the DRE (10-20 
ml), and are stored on ice for less than one hour at the clinic prior to transport to the 
biorepository. Once at the biorepository the samples are centrifuged to remove the 
cellular sediment, aliquoted, and all fractions and aliquots are stored at -80°C. 
Direct EPS samples were collected from patients prior to a radical prostatectomy. 
The collection of this sample involves a vigorous massage of the prostate gland while the 
patient is under anesthesia during the pre-surgery exam, resulting in the collection of pure 
prostatic secretions via the urethra (0.5-1 ml). The sample is then stabilized in a sterile 
saline solution prior to centrifugation to obtain the cellular sediments and subsequently 
aliquoted and stored at -80°C. 
Pools of EPS urine and direct EPS samples were generated based on clinical 
diagnoses. The set of five pools that were previously described in chapter V and were 
created based on the following disease risk stratification: normal, BPH, low PCa, 
intermediate PCa, and high PCa, were used for total glycan analyses of EPS urine fluids 
(Table 1). Each pool comprised of six individual EPS urines; four milliliters per 
individual, for a total volume of 24 milliliters. The individual samples were first 
subjected to a low-speed centrifugation (RT, 5K RPM, five minutes) to remove any 
additional contaminants prior to pooling. The pools were concentrated using Amicon 
Ultra centrifugal filter devices with a 10 kDa cut-off (Millipore, Carrigtwohill, Co. Cork, 
Ireland) and low-speed centrifugation (4°C, 4.5K RPM, approximately 1 hour), resulting 
in a final volume of approximately two milliliters per pool. 
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A set of three EPS urine pools were created based on the following disease risk 
stratification: normal, BPH, and PCa. Each pool comprised often individual EPS urines; 
four milliliters per individual, for a total volume of 40 milliliters. The individual samples 
were first subjected to a low-speed centrifugation (RT, 5K RPM, five minutes) to remove 
any additional contaminants prior to pooling. The pools were concentrated using Amicon 
Ultra centrifugal filter devices with a 10 kDa cut-off (Millipore, Carrigtwohill, Co. Cork, 
Ireland) and low-speed centrifugation (4°C, 4.5K RPM, approximately 1 hour), resulting 
in a final volume of approximately two milliliters per pool. Protein concentrations were 
determined for each enriched pool. These pools were used for ID-PAGE, western 
blotting, TAC, glycan analyses, and glycopeptide analyses. 
A set of direct EPS pools were created based on the following stratifications: low 
risk PCa and intermediate risk PCa (Table 1). Four milliliters each of six samples were 
combined to create each EPS urine pool. These pools were generated following the same 
protocol as for the above sets of pools, with a final volume of approximately two 
milliliters, and protein concentrations were also obtained. This set of pools was used for 
total glycan analyses. 
Thiophilic adsorption chromatography (TAC) 
PSA and PAP were purified from a set EPS urine pools (normal, BPH, PCa) using 
thiophilic adsorption chromatography (TAC) as previously described in chapter III with a 
few adjustments based on the protein concentrations and volumes available for the new 
pools. Briefly, 1.0 milligram of total protein per pool was loaded onto each column with 
a total volume of four milliliters (sample and column buffer). Approximately four 
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milliliters was collected for each unbound fraction, and two milliliters for each 
subsequent fraction. 
N-glycan permethylation 
TAC-purified PSA and PAP gel bands derived from EPS urine pools were 
permethylated195 following trypsin digestion as previously described in chapter III. 
Briefly, gel bands were reduced and alkylated, and then tryptically digested at 37°C for 
18 hours. Next, trypsin was denatured at 100°C for 5 minutes, and PNGase F (New 
England Biolabs, Ipswich, MA) was added to the peptide mixture and incubated at 37°C 
for 18 hours. The resulting sample was purified by CI8 columns and the N-glycans were 
collected in 5% acetic acid, and subsequently dried under reduced pressure. Dried N-
glycans were permethylated following the protocol described by Ciucanu and Kerek195. 
The permethylated N-glycans were purified using CI8 columns, eluted in 85% 
acetonitrile, and then dried under a nitrogen stream. 
In addition to gel bands, total glycan analysis was performed on tryptic peptides 
derived from EPS urine and direct EPS pools. Non-PCa and PCa sample sets were 
created from previously described EPS urine pools. For direct EPS samples, low PCa 
risk and intermediate PCa risk stratifications were used to generate the pooled sample 
sets. Each pool to be permethylated consisted of 180 micrograms of protein, which was 
subsequently precipitated prior to trypsin digestion, PNGase digestion, and 
permethylation. 
MALDI-TOF/TOF 
The dried permethylated N-glycans were prepared and analyzed by MALDI-TOF 
as previously described in chapter III. Briefly, the dried permethylated N-glycans were 
reconstituted in 100% methanol, and the sample was mixed 1:1 with 2,5-
Dihydroxybenzoic acid (DHB) matrix (20mg/ml in 50% methanol), and then spotted on 
the MALDI-TOF target plate. Each sample was analyzed in positive ion mode and 
FlexControl and FlexAnalysis software (Bruker Daltonics, Germany) were used for 
spectra processing. The MALDI-TOF LIFT cell was utilized for MS/MS fragmentation 
analysis of permethylated glycans from total EPS pools. A glycan database offered by 
the Consortium for Functional Glycomics (http://www.functionalglycomics.org) was 
used to search permethylated glycan masses correlating to peaks of interest in MALDI-
TOF spectra, and glycan "cartoons" representing mass peaks were built using 
GlycanBuilder ver 1.2 build 3353196. 
Hybrid triple quadrupole/linear ion trap mass spectrometry 
A hybrid triple quadrupole/linear ion trap mass spectrometer 4000 (QTRAP® 
LC/MS/MS system, Applied Biosystems, Foster City, CA) coupled to a Tempo NanoLC 
system (Eksigent Technologies, Dublin, CA) was used to determine the structures of the 
glycans attached to each of the three PAP linkage sites: Asn-62, Asn-188, and Asn-301. 
The methods described by Sandra et al.197 were used with minor modifications to 
optimize for our samples and instrumentation, and are detailed in chapter III. Figure 19 
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Figure 19. Triple quadrupole ion trap configuration for precursor ion scanning. 
Dried tryptic and chymotryptic peptides are reconstituted in 20 microliters of Buffer A 
(5% acetonitrile/0.1% formic acid/0.005% heptafluorobutyric acid in water) and 8 
microliters per experiment is injected into the nanoLC system for fractionation prior to 
being applied to the nanospray ionization (NSI) source and trapped in quadrupole 0 (Q0). 
Next, the peptides are scanned in quadrupole 1 (Ql) to determine their masses and 
retention times. The peptides then travel to quadrupole 2 (Q2) which acts as a collision 
cell where fragmentation of the parent ions occurs. The ions then reach Quadrupole 3 
(Q3) which is set to transmit only the mass of the diagnostic oxonium ions to the 
detector, such as m/z 163 (Hex+), 204 (HexNAc+), 292/274/256 (NeuAc+1), and 366 
(HexHexNAc+). Upon their detection, an enhanced product ion scan (EPI) of the 
precursor ion is triggered causing fragmentation of the selected parent ions in Q2, then 
fragmented ions are captured in the ion trap and scanned out generating an MS/MS 
spectrum containing ions from the both the peptide and the attached carbohydrate 
structure. Additionally, the charge state of the parent ion will be reported, allowing for 
complete annotation of the spectrum, as illustrated in Figure 13. 
ClinProt computational data analysis 
ClinProt software version 2.0 (Bruker Daltonics, Germany) was used to baseline 
subtract, normalize spectra (using total ion current) and determine peak m/z values and 
intensities in the mass range of 1,000 to 6,000 daltons for the EPS PAP and EPS urine 
total glycan MALDI-TOF data. A mass window of 0.5% was used to align the spectra, 
and a k-nearest neighbor genetic algorithm was used to identify statistically significant 
differences in protein peaks in the three groups analyzed. Comparison of relative peak 
intensity levels between groups was also calculated within the software suite. 
6.3 Results 
Purification of PSA and PAP from EPS urine pools 
Pooled sample sets representative of normal, benign prostatic hyperplasia (BPH) 
and prostate cancer conditions were generated using a biorepository of EPS urine 
1 80 
samples. Thiophilic adsorption chromatography (TAC) was used to purify PSA and 
PAP from the concentrated, pooled EPS urine fluids by batch elution. Approximately six 
milliliters was collected as flow-through and labeled as the unbound fraction, while 
approximately three milliliters was collected for each subsequent salt elution fraction. 
The consequential protein fractions were separated by SDS-PAGE, and it was observed 
that PAP did not bind to the TAC resin, while PSA eluted in the 0.6M, 0.4M, and 0.2M 
sodium sulfate fractions (Figure 20). We detected both PSA and PAP by Coomassie blue 
staining, and PSA and PAP identities were confirmed in their respective fractions by 
western blotting. 
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Figure 20. Thiophilic adsorption chromatography of EPS urine pools. EPS urine 
protein fractions from normal, BPH, and PCa defined pools purified by thiophilic 
adsorption chromatography (TAC) were separated on a 12% Bis-Tris NuPAGE SDS-gel 
(Invitrogen) and silver stained. Proteins that did not bind the TAC resin are shown in the 
lane marked Unbound, with protein from the 0.8M NaS04 elution, 0.6M, 0.4M, 0.2, and 
0 M/25mM HEPES in the following lanes. PAP and PSA identities were confirmed in 
the above fractions by staining and western blots. 
MALDI-TOF analysis of permethylated PSA and PAP glycans from EPS urines 
Permethylation195 of PNGase F cleaved glycans and MALDI-TOF analysis of the 
derivatized structures was performed for each of the EPS urine clinically-defined groups 
in order to further characterize PSA and PAP glycans. For PAP, 36 glycan structures 
were positively identified by MALDI-TOF, with the majority of these being complex 
sub-types, and a few representatives of the high-mannose sub-type were present as well 
(Table 8). For some structures, the sub-type was not able to be determined; however 
these structures would ultimately be classified as either a complex or hybrid subtype. 
Figure 21 represents the MALDI-TOF spectra collected for the permethylated PAP 
glycans from the normal, BPH, and PCa cohorts. Permethylated glycans cleaved from 
PSA in these EPS urine sample pools were not as readily detectable as structures from 
PAP, with only 23 structures being confidently identified (Table 9). The structures 
detected were mostly of the complex and high-mannose sub-types, with these results 
remaining consistent with glycan structures previously reported for PSA arising from 
serum and seminal f lu ids" J" '" ' , as well as seen from our seminal plasma studies 
(Table 3). MALDI-TOF spectra obtained for the PSA glycans for the EPS urine samples 
is shown in Figure 21. 
Triple-quadrupole mass spectrometry analysis of PAP glycopeptides derived from 
EPS urines 
As in aim I, glycopeptide analysis of the three N-linked glycosylation sites for 
PAP found in EPS urine fluids was performed using a triple-quadrupole mass 
spectrometer. PAP-containing EPS urine fractions were separated by SDS-PAGE and 
Table 8. Permethylated PAP glycans from normal, BPH, and PCa EPS urine pools 
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Identified m/z values were used for database searches, and corresponding masses that 
could be assigned to a biologically relevant N-glycan structure are listed. An asterisk 
denotes structures that are one representation of multiple possible glycoforms for a given 
mass. The shown structure in these cases was chosen based on its apparent prevalence in 
mammalian species. Cartoon representations are as follows: • =GlcNAc, • 
=Mannose, O =Galactose, A=Fucose, •=NeuAc, • =GalNAc 
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Figure 21. MALDI-TOF spectra of permethylated PAP glycans derived from EPS 
urine samples. Representative MALDI spectra for permethylated PAP glycans from 
BPH, normal, and PCa disease-defined pools are shown. Glycan structures 
corresponding to detected m/z peaks are listed in Table 8. 
Table 9. Permethylated PSA glycans from normal, BPH, and PCa EPS urine pools 
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Identified m/z values were used for database searches, and corresponding masses that 
could be assigned to a biologically relevant N-glycan structure are listed. An asterisk 
denotes structures that are one representation of multiple possible glycoforms for a given 
mass. The shown structure in these cases was chosen based on its apparent prevalence in 
mammalian species. Cartoon representations are as follows: • =GlcNAc, # 
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Figure 22. MALDI-TOF spectra of permethylated PSA glycans derived from EPS 
urine samples. Representative MALDI spectra for permethylated PSA glycans from 
BPH, normal, and PCa disease-defined pools are shown. Glycan structures 
corresponding to detected m/z peaks are listed in Table 9. 
proteolytically digested with either trypsin or chymotrypsin prior to further sample 
separation by the in-line nanoLC system and mass spectrometry analysis. Precursor ion 
mode was utilized for the detection of oxonium ions 163, 292, and 366 as previously 
described in chapter III. Figure 23 illustrates an identified chymotrypsin digested 
glycopeptide with an attached high mannose glycan structure, while Figure 24 
demonstrates a complex biantennary, singly sialylated N-glycan attached to a tryptic 
glycopeptide. Overall, we identified two complex structures attached to Asn-62, and one 
high mannose structure attached to Asn-301 (Table 10). These data correlate with our 
previous studies using seminal plasma-derived PAP peptides, however we did not 
successfully identify as many glycoforms attached to Asn-62 and Asn-301, nor did we 
positively identify any glycoforms at Asn-188. 
Total glycan analysis of EPS urine and direct EPS pools by MALDI-TOF 
In order to further characterize EPS fluids, glycan analysis on total pools was 
performed. A paired cohort or EPS urines deemed non-cancer and cancer were used as 
representatives of EPS urine fluids. The non-cancer pool consisted of normal and BPH 
classified individuals, while the cancer pool was generated from individuals with low, 
intermediate, or high-risk diagnosed prostate cancer. Each pool contained a total of 180 
micrograms of protein (90 micrograms each of normal and BPH; 60 micrograms each of 
low, intermediate, and high risk PCa), and the pools were precipitated with 10% TCA 
prior to trypsin digestion. For direct EPS samples, a pool of low-risk prostate cancer 
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Figure 23. Precursor ion scan for 163 m/z hexose of chymotryptic EPS urine PAP 
peptides. A) Enhanced Product Ion (EPI) scan of a quadrupole-charged PAP 
glycopeptide with parent mass of 2929.35. B) Expanded window of above EPI scan 
showing fragmentation of the parent ion that corresponds to the chymotryptic peptide 
RNETQHEPYPLM containing the glycosylation site Asn-301 and a Man6 N-glycan. 
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Figure 24. Precursor ion scan for 366 m/z hexose of tryptic EPS urine PAP 
peptides. A) Enhanced Product Ion (EPI) scan of a quadrupole-charged PAP 
glycopeptide with parent mass of 2816.31. B) Expanded window of above EPI scan 
showing fragmentation of the parent ion that corresponds to the tryptic peptide 
FLNESYK containing the glycosylation site Asn-62 and a complex biantennary, singly 
sialylated N-glycan. 
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Table 10. EPS urine PAP glycopeptides and their corresponding N-glycan 
structures identified by triple quadrupole MS/MS analysis 
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Both tryptic and chymotryptic PAP digests were analyzed by the QTRAP as described in 
the experimental section. PI scans for oxonium ions 163, 366, and 292 are represented in 
the above table. Certain EPI scans revealed glycopeptide information that allowed for the 
assignment of both peptide and glycan. 
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individuals, with each pool containing 180 micrograms of total protein. These pools 
were also TCA precipitated and trypsin digested. The tryptic digestions were then treated 
with PNGase F and permethylated. The permethylated glycans were analyzed by 
MALDI-TOF/TOF (Figure 25 and Figure 26). Forty-three glycans were positively 
identified from the EPS urine fluids, while direct EPS fluids yielded 24 glycan structures 
(Table 11 and Table 12). For both EPS urine and direct EPS samples, mostly complex 
subtype glycans were observed, with some high-mannose and hybrid subtypes 
represented as well. There was extensive branching, sialylation, and fucosylation 
detected in all sample sets (Table 11 and Table 12), indicating the complexity of these 
fluids as well as the presence of many glycosylated proteins. Due to the high 
concentration of the EPS fluids, the mass spectra resulted in very intense peaks, thus 
allowing for MS/MS fragmentation analysis of several glycan structures. A 
representation of MALDI-TOF/TOF LIFT spectra is shown in Figure 27, demonstrating 
the fragmentation pattern of a permethylated complex, biantennary glycan containing one 
terminal sialic acid by the MALDI-TOF/TOF instrument. 
Detection of fucosylation differences among disease states by ClinProt data analysis 
Clinprot software (version 2.0) was used to analyze MALDI-TOF spectra for EPS 
urine PAP and EPS urine total glycan samples (Figure 21 and Figure 25). From these 
analyses, we found that glycan structures without a core fucosylation were represented in 
equivalent abundance among different disease states (i.e. normal, BPH, PCa), with an 
example shown in Figure 28. In comparison, we observed an overall decrease in 
intensity of fucosylated species in the cancer samples as compared to non-cancer 
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Figure 25. MALDI-TOF spectra of EPS urine N-glycans. Representative MALDI 
spectra for permethylated N-glycans from non-PCa and PCa disease-defined EPS urine 
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Figure 26. MALDI-TOF spectra for permethylated direct EPS N-glycans. 
Representative MALDI spectra for permethylated N-glycans from low risk PCa and 
intermediate risk PCa disease-defined direct EPS pools are shown. Glycan structures 
corresponding to detected m/z peaks are listed in Table 12. 
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Identified m/z values were used for database searches, and corresponding masses that 
could be assigned to a biologically relevant N-glycan structure are listed. An asterisk 
denotes structures that are one representation of multiple possible glycoforms for a given 
mass. The shown structure in these cases was chosen based on its apparent prevalence in 
mammalian species. Cartoon representations are as follows: • =GlcNAc, • 
=Mannose, O =Galactose, A=Fucose, ^=NeuAc, • =GalNAc 
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Identified m/z values were used for database searches, and corresponding masses that 
could be assigned to a biologically relevant N-glycan structure are listed. An asterisk 
denotes structures that are one representation of multiple possible glycoforms for a given 
mass. The shown structure in these cases was chosen based on its apparent prevalence in 
mammalian species. Cartoon representations are as follows: • =GlcNAc, • 
=Mannose, O =Galactose, A=Fucose, •=NeuAc, • =GalNAc 
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Figure 27. MALDI-TOF/TOF LIFT spectra of a permethylated glycan structure 
from EPS urine. A representative LIFT spectra indicating the fragmentation of parent 
mass 2430.78 detected in the spectra from Figure 25 is shown. Known masses of 
common fragmentation patterns were used to annotate the data. Cartoon representations 
are as follows: • =GlcNAc, O =Mannose, 0 =Galactose, A=Fucose, ^=NeuAc, • 
=GalNAc 
Figure 28. Heat map overview of MALDI-TOF spectra for peak 2793. MALDI-TOF 
spectra generated from EPS urine PAP samples were analyzed with Clinprot software, 
indicating the intensity of the spectra from each sample cohort as compared to the next. 
Each box represents spectra from one group, with normal being on top, BPH in the 
middle, and prostate cancer on the bottom. Arrows show the peak height for each 
corresponding heat map. Peak 2793 represents a complex, biantennary glycan with two 
terminal sialic acids. Cartoon representations are as follows: • =GlcNAc, 9 
=Mannose, 0 =Galactose, A=Fucose, ^=NeuAc, • =GalNAc 
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Figure 29. Heat map overview of MALDI-TOF spectra for peak 2967. MALDI-TOF 
spectra generated from EPS urine PAP samples were analyzed with Clinprot software, 
indicating the intensity of the spectra from each sample cohort as compared to the next. 
Each box represents spectra from one group, with normal being on top, BPH in the 
middle, and prostate cancer on the bottom. Arrows show the peak height for each 
corresponding heat map. Peak 2967 represents a complex, biantennary glycan with two 
terminal sialic acids and a core fucose residue. Cartoon representations are as follows: 
• =GlcNAc, O =Mannose, 0 =Galactose, A=Fucose, ^=NeuAc, D=GalNAc 
differential between cancer and non-cancer samples were of the complex sub-type, with 
various branching and terminal sialic acids. 
6.4 Discussion 
Using serum and plasma for biomarker discovery has proven to be difficult for 
many laboratories, therefore demanding the need for enriched sources of lower abundant 
proteins which are capable of differentiating between disease and non-disease states. 
While it is commonly known that both tissues and proximal fluids are enriched for 
potential biomarkers, the collection of such samples is not always within the parameters 
of a given study. For our studies, we have found that EPS urine fluids are readily 
obtained in the clinical setting, and are enriched for proteins directly related to the 
prostate, thus making these fluids ideal for biomarker discovery for the detection of early 
prostate cancer. In addition, EPS urines can be obtained at a routine physical exam, 
making it not only ideal for discovery, but also for clinical applications as a source of 
diagnostic markers for clinical assays. Direct EPS fluids are also enriched for prostate-
derived proteins and are a great discovery tool, however due to their method of 
collection, they may not have utility for validation nor for future clinical assays. 
Because glycosylation is known to be important to all aspects of cancer 
progression83' 93,214? the glycan profiles of clinically-relevant samples may provide the 
much needed diagnostic markers for early prostate carcinomas. While serum PSA is the 
current FDA-approved biomarker for prostate cancer, it is not without faults. Serum PSA 
has proven to be organ-specific, but is not cancer-specific, as elevated serum PSA levels 
are detected with BPH conditions as well37"39. Additionally, a more current problem 
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facing clinicians today is determining which patients have significant prostate cancer, 
indicating they indeed need radical surgery and treatment as compared to patients who in 
fact have indolent prostate cancer. In approximately 80% of radical prostatectomies it is 
found that the patient's prostate cancer was not expected to be an aggressive lethal form 
of tumor, despite their clinical risk factors indicating a different prognosis. This aspect 
alone reiterates why better biomarkers are needed for distinguishing clinically significant 
or aggressive forms of prostate cancers from more indolent tumors. 
Being a glandular organ, the prostate is constantly secreting fluids full of proteins, 
most of which are glycosylated. PSA and PAP are two prominent prostate-specific 
proteins, and both are N-glycosylated, making them ideal targets for glycomic studies. 
Based on preliminary studies, we have identified 36 different PAP glycoforms in EPS 
urines, as compared to the 21 PAP glycoforms identified in our prior seminal plasma 
studies. Nineteen of these structures overlap between seminal plasma and EPS urines 
(Table 13). As seen with seminal plasma-derived PAP, the PAP glycoforms in EPS 
urines are mostly of the complex subtype, with multiple branching, sialylation, and 
fucosylation (Table 8). For EPS urine PSA, we observed 23 glycan structures, as 
compared to the 40 different glycoforms identified for seminal plasma PSA (Table 9). 
One explanation for this marked difference can be due to the dilution factor of EPS urines 
as compared to seminal plasma, as well as other experimental aspects. Further analysis 
of EPS urine PSA glycoforms will be necessary to appropriately compare these structures 
to those observed in seminal plasma samples. 
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Identified m/z values were used for database searches, and corresponding masses that 
could be assigned to a biologically relevant N-glycan structure are listed. An asterisk 
denotes structures that are one representation of multiple possible glycoforms for a given 
mass. The shown structure in these cases was chosen based on its apparent prevalence in 
mammalian species. Cartoon representations are as follows: • =GlcNAc, • 
=Mannose, O =Galactose, A=Fucose, ^NeuAc, • =GalNAc 
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We also wanted to identify individual glycans attached to each N-linked site on 
PAP using triple-quadrupole mass spectrometry, similar to those studies performed in 
Aim I with seminal plasma fluids. Table 10 shows the structures and their respective 
tryptic and chymotryptic peptides we observed using the precursor ion scan mode with 
nanoLC-triple quadrupole MS/MS for diagnostic oxonium ions 163, 292, and 366. 
While we did not identify as many glycopeptides as seen with our seminal plasma 
studies, we were still successful in identifying three glycans, five tryptic glycopeptides, 
and two chymotryptic glycopeptides. One explanation for less coverage with EPS urine-
derived PAP is the dilute nature of EPS urines as compared to seminal plasma. While 
EPS urines are enriched for PAP as compared to serum or plasma, it is not as 
concentrated as seminal fluid. Another possible explanation could be a decreased 
efficiency of chymotryptic digestion with the EPS urine studies, as the limited coverage 
observed arose from the chymotryptic digested experiments. 
In addition to protein-targeted analyses, another useful glycomic approach 
involves the examination of the global glycosylation patterns for a given sample set. 
With this approach, one may observe an overall trend that differentiates between disease 
states. We used the total glycan approach with both EPS urine and direct EPS samples 
with the intention of examining the glycan structural isoforms (also termed glycoforms) 
present and monitoring for any significant changes between disease states and differing 
risk stratifications. Through our permethylation assays, we identified 43 glycoforms 
derived from EPS urines and 24 glycoforms from direct EPS fluids (Table 11 and Table 
12). It is imperative to note that the glycoforms observed are structural representations of 
any number of anomeric isoforms. Therefore, while we are reporting a finite number of 
125 
structures, there are possibly many more glycoforms present, which will require 
additional analyses to define. When comparing non-PCa and PCa EPS urine PAP pools, 
we see an overall trend of a decrease in fucosylated species in the PCa pools as compared 
to the non-PCa pools, as represented by Figure 28 and Figure 29. Figure 28 depicts a 
non-fucosylated, biantennary complex glycan, and shows that the peak intensities are 
similar across the three groups, normal, BPH, and PCa. In contrast, Figure 29 shows the 
same complex glycan with a core fucose residue, with a marked decrease in peak 
intensity for the cancer group as compared to normal and BPH. These changes in 
fucosylation complement other studies indicating changes in fucosylation with cancerous 
states215"219. These data support the validity of EPS fluids as an excellent source for 
identifying potential carbohydrate-based biomarkers. 
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CHAPTER VI 
CONCLUSIONS AND FUTURE DIRECTIONS 
6.1 Aim I (Chapter III): Develop methodologies for the characterization of N-linked 
glycans of prostate-specific antigen and prostatic acid phosphatase in seminal fluids. 
A. The results from this aim indicate that N-linked glycosylation of seminal 
plasma-derived PSA and PAP is very heterogeneous. In addition, we observed altered 
glycosylation trends across normal, BPH, and PCa disease states for PAP. 
B. Thiophilic adsorption chromatography (TAC) of disease-defined seminal 
plasma pools successfully fractionated the protein mixture, providing further purified 
forms of PSA and PAP. PAP did not bind the TAC resin, and therefore was collected in 
the unbound fraction along with albumin and other non-binding proteins, as indicated by 
western blot analysis. We also observed by western blot analysis that PSA elutes in two 
separate fractions, those of 0.6M and 0.4M sodium sulfate concentration. We confirmed 
PSA and PAP identity by in-gel trypsin digestion and peptide mass fingerprint (PMF) 
analysis with MALDI-TOF mass spectrometry. This mass spectrometry analysis resulted 
in the statistically significant identification of both PSA and PAP, without the detection 
of any other proteins in the digested gel slice. 
C. Normal phase HPLC separation of 2-AB derivatized N-linked glycans was 
completed on PSA and PAP isolated from normal, BPH, and PCa seminal plasma pools, 
with or without sialidase treatment. These results indicate clear differences among 
disease states for PAP glycans, in particular when comparing normal and BPH samples to 
cancer samples. A decrease in bi- and tetraantennary fucosylated structures as well as 
127 
high mannose structures is observed for PAP arising from cancer samples as compared to 
normal and BPH conditions. While no overall trend in disease-specific glycan changes 
detected for PSA were observed for PSA glycans, the N-glycans identified were 
consistent with previously reported structures observed for PSA, with high representation 
of bi, tri-, and tetraantennary core fucosylated complex structures. 
D. MALDI-TOF analysis of permethylated N-linked glycans yielded positive 
identification of 40 PSA glycan structures and 21 PAP glycan structures. While the 
majority of these structures are of the complex sub-type, we did observe a smaller 
representation of both high-mannose and hybrid sub-types. The PSA and PAP N-glycan 
structures identified by MALDI-TOF correlate well with the structures observed by our 
HPLC separation, and remain consistent with previously published data. 
E. Triple quadrupole mass spectrometry analysis of PAP glycopeptides enabled 
us to determine which subtype of N-glycans are attached at each of the three N-linked 
glycosylation sites for PAP. We observed bi- and triantennary sialylated structures at 
Asn-62, bi- and tetraantennary sialylated structures at Asn-188, and high mannose 
structures at Asn-301. Tryptic digestion of PAP did not allow for the elucidation of any 
structures at Asn-188; however chymotryptic digestion of PAP created smaller 
glycopeptides, therefore bringing the glycopeptides into the range of detection for the 
triple quadrupole instrument. The observed high mannose structures present at Asn-301 
and complex structures at Asn-188 correlate with previously published data on the crystal 
structure of PAP. It was previously thought that high mannose structures must be present 
at Asn-62; however we have confirmed the presence of complex structures at this N-
linked glycosylation site, with no evidence of a high-mannose structure present at this 
site. 
6.2 Aim II (Chapter IV): Establish expressed prostatic secretions as a source of 
prostate specific antigen and prostatic acid phosphatase. 
A. The results from this aim indicate that both EPS urine and direct EPS fluids 
are indeed an enriched source of PSA and PAP. Both prostate cancer biomarkers are 
readily detected in EPS fluids, and these fluids are compatible with our proteomic assays, 
allowing for future, more in-depth analyses using EPS fluids. 
B. A pre-DRE urine and a post-DRE "EPS" urine sample were collected from an 
individual patient, on the same day, within one hour of each other. These samples were 
analyzed and compared for their protein content by both 2D-PAGE and LC-ESI-MS/MS. 
We observed relative protein differences between pre-DRE and post-DRE urines by 
visualizing the spot patterns of 2D-PAGE separation of the proteins in each sample with 
silver staining. Protein identification by mass spectrometry revealed an increase in the 
number of significantly scored proteins present in the post-DRE urine as compared to the 
pre-DRE urine. In addition, PSA and PAP were not identified in the pre-DRE urine; 
however they were in the top 10 significant protein hits in the post-DRE urine. 
C. Direct EPS fluid from one individual was analyzed by LC-ESI-MS/MS in 
order to determine the proteins present in this prostatic fluid. We observed a large 
number of proteins significantly identified in the direct EPS fluid, with PSA and PAP 
both being in the top 10 significant hits. These results confirm that this fluid is indeed a 
great source of PSA and PAP, and thus could be used in future proteomic and glycomic 
studies with the intention of discovering enhanced biomarkers for the early diagnosis and 
prognosis of prostate carcinomas. 
D. Thiophilic adsorption chromatography (TAC) was utilized in order to 
fractionate EPS urine disease-define pools with the intent of obtaining purified forms of 
PSA and PAP for further analyses. PAP did not bind the TAC resin and therefore was 
collected in the unbound fraction, as was detected by ID-PAGE and western blotting. 
PSA eluted in the 0.6M, 0.4M, and 0.2M sodium sulfate fractions, which was also 
determined by ID-PAGE and western blotting. MALDI-TOF PMF analysis was used to 
confirm the identities of PSA and PAP which were run on ID-PAGE, excised, and in-gel 
trypsin digested. 
E. 2D-PAGE followed by western blotting was used in order to further examine 
PSA and PAP characteristics in EPS fluids. A large pool of EPS urines were separated 
by 2D-PAGE in duplicate, with one resulting gel being silver stained and the other gel 
being transferred to PVDF membrane for western blot analysis of PSA and PAP. The 
results from this analysis positively confirm the presence of multiple PSA and PAP 
isoforms in EPS urines, most of which are likely glycoforms that can be targeted in 
further studies. 
F. ELISA analysis of PSA and PAP concentrations in individual EPS urine and 
direct EPS samples was performed in order to determine PSA and PAP levels in prostatic 
proximal fluids. We observed an overall decrease of both PSA and PAP levels in cancer 
samples as compared to non-cancer samples, with a detection range of 10-40 ug/ml for 
PSA and 3-10 ug/ml for PAP in EPS urines and a range of 80-120 ug/ml for PSA and 20-
40 ug/ml for PAP in direct EPS fluids. These results indicate that PSA and PAP are less 
130 
prevalent in cancerous tissue as compared to normal and BPH tissues, however larger 
sample cohorts are necessary in order to truly understanding the status of these 
biomarkers in the diseased prostate. 
6.3 Aim III (Chapter V): Application of new methodologies to expressed prostatic 
secretions for prostate cancer glycoprotein biomarker discovery. 
A. The results from this aim indicate that protein-specific and total glycomic 
analyses can be performed using EPS urine and direct EPS fluids. We positively 
identified N-linked glycans for both PSA and PAP derived from EPS urines. In addition 
we observed a number of N-linked glycans in disease-defined pools of EPS urine and 
direct EPS fluids, indicating the feasibility of discovering new candidate carbohydrate-
based biomarkers in EPS fluids for the early diagnosis and prognosis of prostate 
carcinomas. 
B. Normal, BPH, and PCa disease-defined pools of EPS urines were generated 
and subsequently fractionated using thiophilic adsorption chromatography (TAC). As 
seen previously, PAP did not bind the TAC resin and was collected in the unbound 
fraction, while PSA eluted in the 0.6M, 0.4M, and 0.2M sodium sulfate fractions. PSA 
and PAP identities were positively confirmed in their respective fractions by silver 
staining and western blotting. 
C. MALDI-TOF analysis of permethylated N-linked glycans was performed for 
PSA and PAP derived from EPS urine disease-defined pools (normal, BPH, PCa). We 
observed a total of 23 glycoforms for PSA and 36 glycoforms for PAP, with mostly 
complex subtypes being represented. High mannose and hybrid subtypes were also 
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present for PSA, with only the addition of high mannose structures positively identified 
for PAP. There were a number of glycoforms for PAP that the subtype could not be 
determined as either complex or hybrid. For both PSA and PAP, the complex glycans 
observed often contained terminal sialic acid residues and core fucose residues. 
D. Triple quadrupole MS was used in the precursor ion scanning mode to 
examine the N-glycan subtypes present at each N-linked glycosylation site of PAP. After 
multiple experiments using the 163, 292, and 366 diagnostic ion masses, and using both 
trypsin and chymotrypsin digested PAP, we observed biantennary complex structures at 
Asn-62 and high mannose structures at Asn-301. We were unable to confirm the 
presence of any structures at Asn-188, which had proven to be difficult in our previous 
analyses using seminal plasma-derived PAP. These differences are likely due to either 
sample concentration, protease digestion efficiency, or both. 
E. Total glycan analysis of permethylated N-linked glycans from EPS fluids was 
performed using MALDI-TOF. EPS urine pools defined as non-PCa and PCa resulted in 
a total of 43 glyco forms, while direct EPS pools (low risk PCa and intermediate risk PCa) 
resulted in 24 glycoforms. Again, complex N-linked glycan subtypes comprise the 
majority of glycoforms observed, with high mannose and hybrid structures also 
represented. Due to the high concentration of glycans present in the sample, 
fragmentation of a subset of individual glycoforms was accomplished using MALDI-
TOF /TOF LIFT. This type of fragmentation is typically not performed, as ESI-MS/MS 
with an ion trap is the preferred instrumentation used for glycan fragmentation. We 
detected near complete fragmentation by manual annotation of the spectra, and likely 
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could confirm the presence of complete fragmentation with appropriate bioinformatic 
tools. 
F. Clinprot software data analysis was performed on EPS urine PAP glycan and 
EPS urine total MALDI-TOF spectra. We observed an overall trend of decreased 
fucosylation in cancer samples as compared to normal and BPH samples. These results 
indicate that for PAP, and potentially other glycoproteins derived from the prostate, there 
is less fucosylation occurring in a cancerous prostate. These glycan targets will be useful 
for examining larger sample cohorts and determining the utility of a glycan-based 
biomarker for the detection or early prostate carcinomas, as well as distinguishing 
between significant and insignificant prostate carcinomas. 
6.4 Concluding Remarks and Future Directions of Aims I, II, and III 
Based on our present studies, we have gained knowledge about and catalogued 
the type of N-linked glycoforms attached to PSA and PAP in prostatic fluids. 
Additionally we have preliminary data confirming N-linked glycan differences among 
disease states (normal, benign, PCa) for PAP in seminal fluid and EPS. However, more 
in-depth studies are necessary to further elucidate novel candidate biomarkers for the 
early diagnosis and prognosis of prostate cancer. It has become common knowledge that 
while serum PSA is the best biomarker currently available for the detection of prostate 
carcinomas, especially when it is used in conjunction with a DRE exam, there is still a 
pressing need for better biomarkers. Many prostate cancers being detected today are in 
fact indolent diseases, and do not pose any lethal danger to the patient. Therefore, many 
patients are undergoing unnecessary biopsies, surgeries, and treatments, all of which can 
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cause physical and emotional hardships. Additionally, some patients suffer more from 
the resulting health complications that can develop post-treatment or post-surgery than 
they would have if their prostate cancer had remained untouched. A new classification 
scheme is being developed which differentiates between significant and insignificant 
prostate carcinomas. Under these new definitions, significant disease represent tumors 
which are most likely to progress to more aggressive cancers and therefore need to be 
treated, while insignificant disease represent tumors are least likely to progress and not 
affect the patient's life expectancy or livelihood. However, these classifications are 
currently only determined after the patient has undergone a radical prostatectomy, and 
examination of the removed prostate by a highly-specialized pathologist. In order to help 
future patients, a way to better determine these classifications prior to surgery or several 
biopsies is essential. 
Because protein glycosylation has been shown to be involved in every aspect of 
cancer progression , it is plausible that the altered glycans can be detected reliably, 
further validated, and ultimately used in high-throughput clinical-based assays. PSA has 
one N-linked glycosylation site, while PAP contains three N-linked glycosylation sites, 
all of which have been confirmed to be occupied by glycans120,124'125. PAP has been 
extensively reported in the literature to have wide-spread distribution throughout human 
tissue ' , with past clinical assays relying solely on its enzymatic activity. Eventually 
it was found that the PAP activity being assayed in blood could not be correlated back to 
the prostate as the sole source of PAP. We have circumvented this issue by focusing on 
forms of PAP derived directly from prostatic fluids instead of from serum or plasma. Not 
only are we now analyzing prostate-specific PAP, these fluids are enriched for PAP as 
compared to serum or plasma. For PSA, while it has been shown to be prostate-specific, 
and therefore still has high specificity when used in serum-based clinical assays, we are 
able to obtain enriched PSA by using our prostatic fluids. 
Another advantage we have lies in our vast biorepository of seminal fluids and 
expressed prostatic secretions, with EPS collection an ongoing process with growing 
numbers of collections. In addition, we are collecting EPS fluids for different cohorts of 
patients, including but not limited to healthy, normal patients and patients with BPH or 
prostate cancer. We also have been able to classify the prostate cancer samples into 
different risk stratifications, giving us many different possible cohorts to examine for 
glycosylation changes to PSA and PAP. 
Glycomic analyses do not always have to be performed on individual proteins in 
order to provide useful information, in fact, analysis of global glycomic changes have 
been reported175'176. These methods search for an overall alteration to glycosylation 
patterns in a given disease state which, in turn, is reflective of all proteins contributing to 
the glycosylation changes. Our studies have provided basic knowledge of the most 
abundant glycan structures present in EPS fluids, as well as those attached specifically to 
PSA and PAP. However, deeper analyses are necessary in order to identify less common 
structures, as well as to determine the changes that are occurring between disease states. 
We have observed trends indicating a decrease in overall levels of fucosylation when 
comparing prostate cancer samples to normal and BPH samples. Now that we have 
candidate glycoforms, additional analyses will be needed to confirm whether the 
differences seen are maintained in larger cohorts of individual samples. To do so, 
optimization of current methodologies as well as the addition of enhanced glycomic 
strategies is required. 
First, permethylated N-linked glycans can be readily detected by MALDI-TOF. 
This derivatization method stabilizes the glycans, more specifically the terminal sialic 
acid residues, as well as simplifies the resultant spectra by producing only sodium ion 
adducts. However, our current scheme utilizes a well-established liquid-phase 
permethylation technique195 that does not allow for high-throughput analyses. While we 
are able to obtain robust results from this method, we can only analyze small numbers of 
samples at one time (n<=5), and it is a slow, tedious process. To overcome this time-
consuming dilemma, a solid-phase permethylation approach may be implemented. This 
method calls for either the use of capillary columns or spin-columns, both of which allow 
for more rapid permethylation of each sample, and for higher amounts of samples to be 
processed at one time ' . In addition to its high-throughput nature, the solid-phase 
protocol is highly quantitative and allows for the higher recovery of sample, therefore 
decreasing the amount of starting material needed for satisfactory results223. We would 
like to utilize the spin-column method, where the limiting factor is the number of sample 
holders in the centrifuge rotor (i.e. n=18-30). In this method, microcentrifuge spin-
columns are used for the clean-up steps of the cleaved glycans prior to permethylation 
and the permethylation reaction itself. Sodium hydroxide beads bathed in acetonitrile are 
added to empty spin columns with an optimal bed volume, washed with DMSO, and the 
sample combined with iodomethane (source of methyl groups) is applied to the column 
up to 8 times repeatedly, and in a matter of minutes, the reaction is complete and ready 
for the final liquid-liquid (water-chloroform) extraction step. Not only does this method 
require less time at the bench, it has also been shown to provide more complete 
permethylation as compared to the liquid-phase method . 
After employing the front-end sample preparative steps in a more rapid fashion, 
the mass spectrometry platforms need to be addressed. Our current MALDI-TOF 
analysis provides us with intact glycan information, giving us the mass of the parent 
structure which we can use to search a public database for potential structural matches. 
However, at this time, we are unable to determine the linkage information by MS/MS on 
the MALDI-TOF instrument for most samples. Fragmentation analysis with an ESI-LIT 
MS/MS instrument (i.e. ThermoFinnegan LTQ or Applied Biosystems QTRAP) will 
allow for input of small quantities of samples and subsequently resulting in the structural 
information necessary to determine monosaccharide linkage data. 
Once the data has been collected, computer software programs are indispensable 
in the actual assignment of the structural linkages. One example of such commercially 
available software is SimGlycan (Applied Biosystems/PremierBiosoft), which takes 
MS/MS data directly from Applied Biosystems (ABI) and Bruker instruments, as well as 
accepts data from other mass spectrometers after a file conversion. The software needs 
user input of a number of factors such as the parent mass of the fragmented structure, the 
charge state of the parent mass, whether or not the structure has been derivatized. Also, 
if the experimental spectrum is derived from a glycopeptide instead of a cleaved glycan 
structure, then the user will need to also input peptide information such as the amino acid 
sequence and any peptide modifications that may be present. The software then takes all 
of the MS/MS masses and searches an internally developed glycan database, annotates 
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the data, and provides the user with a list of potential glycoforms that can fit the spectrum 
data provided. 
Finally, after candidate glycoforms have been discovered by the above sample 
preparative steps and mass spectrometry analyses, validation of such structures is 
necessary, and subsequently clinical assays need to be developed that can accommodate 
the high-throughput detection of the given carbohydrate markers. One particular assay 
that will fit these criteria is the lectin fluorophore-linked immunosorbent (FLISA) 
assay199'216. This type of plate-based assay is similar to a sandwich ELISA assay in the 
sense that an antibody is used to capture the target protein, and then a lectin is used to 
detect and measure the specified monosaccharide on that protein, versus using a second 
antibody to detect and measure the protein of interest. For example, since the 
fucosylation state of various N-linked complex glycans is seen to be differential between 
disease states, this is a good candidate monosaccharide target to begin with. For the 
lectin FLISA, it is imperative to make sure that the capture antibody be modified if it is a 
glycosylated protein, therefore in the case of a fucose-targeted assay, the antibody will 
need to be defucosylated using a competing sugar such as alpha-galactose216. After the 
plate wells are coated with the modified capture antibody, the experimental sample (i.e. 
serum, EPS urine fluid) is added to the wells and allowed to bind prior to the addition of 
a conjugated lectin (i.e. biotin-AAL). Finally the bound lectin is detected using an 
appropriate system (i.e. conjugated-streptavidin) and the signal intensity is measured with 
the preferred system216. With this lectin FLISA assay, the amount of fucosylation in a 
given sample can be detected, and like a protein-based biomarker, a threshold can be set 
indicating at what level the fucosylation indicates disease versus non-disease. For some 
cases, it may not simply be one monosaccharide contributing to the disease state, and 
therefore a panel of monosaccharides will be measured and used together to determine 
the disease state. In the case of prostate cancer, ideally these glycan changes will allow 
for differentiation between insignificant and significant disease, allowing for better 
patient prognosis profiles and therefore decreasing the number of unnecessary biopsies, 
treatments, and radical surgeries in men afflicted with prostate carcinomas. 
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